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List of Abbreviations 
MS Metabolic syndrome 
CVD Cardiovascular disease 
AT Adipose tissue 
T2DM Type 2 diabetes mellitus  
11β-HSD1 11β-Hydroxysteroid dehydrogenase type 1  
TNFα Tumour-necrosis factor α 
IL-6  Interleukin-6 
CCL2 or MCP-1 CC-chemokine ligand 2 
PAI-1 Plasminogen-activator inhibitor type 1 
AdipoR Adiponectin receptor 
AMPK AMP-activated protein kinase 
IL-1RA IL-1 receptor antagonist 
IFN-γ Interferon- γ 
TLR Toll-like receptors 
NF-κB factor nuclear kappa B 
LMW and HMW  Low- and high- molecular-weight 
SRB1 Scavenger receptor class B type 1 
PPARs Peroxisome proliferator-activated receptors 
CXCL8/ IL-8 CXC-chemokine ligand 8 
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VCAM-1 Vascular cell adhesion molecule-1 
E-selectin Endothelial-leukocyte adhesion molecule-1 
ICAM-1 Intracellular adhesion molecule-1 
SREBP1 Sterol regulatory element-binding protein 1 
OBRb Leptin receptor 
cAMP Cyclic adenosine monophosphate 
PKA cAMP-dependent protein kinase A 
ERK Extracellular-signal-regulated kinase 
MAPK p38 mitogen-activated protein kinases 
NK cells Natural killer-cells 
iNOS Inducible nitric-oxide synthase 
ROS Reactive oxygen species 
TNFR TNF receptor 
IKKβ Inhibitor of NF-κB kinase-β  
JNK JUN N-terminal kinase  
ER Endoplasmic-reticulum  
IRS1 Insulin receptor substrate 1  
WAT White AT  
UCP Uncoupling protein  
CAP1 Adenylyl cyclase-associated protein 1  
ET-1 Endothelin-1  
CCR2 CCL2 receptor  
FFA Free fatty acids  
AR Adrenoceptors  
NPs Natriuretic peptides 
ANP Atrial natriuretic peptide 
BNP Brain natriuretic peptide 
AC Adenylate cyclase  
cGMP Cyclic guanosine monophosphate  
PKG cGMP-dependent protein kinase 
GC Guanylyl cyclase  
TG Triglycerides 
ATGL Triglyceride lipase  
HSL Hormone-sensitive lipase  
MGL Monoacylglycerol lipase  
PI3-K Phosphoinositide 3-kinase-dependent  
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PKB/Akt Protein kinase B  
PDE3B Phosphodiesterase 3B  
AC Adenylyl cyclase  
PGC-1α PPARγ coactivator 1  
ACS Acyl-CoA synthetase  
CD36/FAT Fatty acid translocase  
MCD Malonyl-CoA decarboxylase  
CPT-1 Carnitine palmitoyl transferase 1  
SIRT1 Sirtuin 1  
BAT Brown adipose tissue  
PRDM16 PR domain containing 16  
HDLs High-density lipoproteins 
apo apolipoproteins 
ABCA1 ATP binding cassette A1  
LPL Lipoprotein lipase  
VLDL Very low-density lipoprotein  
Glycerol-3P Glycerol-3-phosphate  
DGAT Diacylglycerol acyltransferase  
GLUT4 Glucose transporter type 4  
ACC Acetyl-coenzyme A carboxylase  
BMPs Bone morphogenetic proteins 
C/EBP CCATT enhancer-binding proteins  
RXRα Retinoid X receptor-α  
FABP4 Fatty acid-binding protein-4  
SCD1 Stearoyl-coA desaturase-1 
SRE Sterol response elements  
FAS Fatty acid synthase  
CEPT Cholesteryl ester transfer protein  
PCSK9 Proprotein convertase subtilisin/kexin type 9  
LDL Low density lipoprotein  
HMG-CoA 3-hydroxy-3-methyl-glutaryl-coenzyme A  
MEKK1 Mitogen-activated protein kinase kinase Kinase 1  
HFD High fat diet  
ox-LDL Oxidized LDL 
SCAT Subcutaneous AT  
PPRE Peroxisome proliferators response element  
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ACO Acyl-CoA oxidase  
VAT Visceral AT 
CD40 Cluster of differentiation 40  
AOX1 Aldehyde oxidase 1  
PUFAs Polyunsaturated fatty acids  
LXRα Liver X receptor alpha 
CRP C-reactive protein  
NA Noradrenaline 
5-HT 5-hydroxytryptamine  
DA Dopamine  
POMCs Pro-opiomelanocortin  
MC Melanocortin  
AMPA  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
GABA Gamma-aminobutyric acid  
GLP-1RA Glucagon-like peptide 1 receptor agonist  
ZAG Zinc alpha2 glycoprotein 
FGF21 Fibroblast growth factor-21  
Abstract 
Metabolic syndrome (MS) can be defined as a state of disturbed metabolic homeostasis charac-
terized by the combination of visceral obesity, atherogenic dyslipidemia, arterial hypertension 
and insulin resistance. The growing prevalence of MS will contribute to the burden of cardiovas-
cular disease (CVD). Obesity and dyslipidemia are main features of MS and both can present with 
adipose tissue (AT) dysfunction, involved in the pathogenic mechanisms underlying MS. Con-
sidering this, increase the knowledge about the role of AT and the drugs that modulate its func-
tions can become the next step in order to tackle these diseases. In this article, we revised the 
effects of the current approved drugs for dyslipidemia and obesity treatment on AT and their 
underlying mechanisms. Their main adipocyte effects upon metabolism, inflammation, athero-
genesis, insulin sensitivity, and adipogenesis were reviewed to explore how these drugs can mod-
ulate these complex pathways. Furthermore, we denote differences between drugs of the same 
class and that, despite a favorable clinical effect, some drugs can have adverse effects on adipo-
cyte functions. Summing up, it is important to question whether answers to these problems will 
be found in new advances in pharmacology or in further adjustments and combinations between 
drugs already developed. To better understand the effect of drugs used in dyslipidemia and obesity 
on AT is not only challenging for physicians but could be the next step to tackle CVD. 
Key words:  Adipose Tissue; Dyslipidemia; Obesity; Anti-dyslipidemic drugs; Anti-obesity 
drugs. 
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1 Introduction 
Metabolic syndrome (MS) is a cluster of metabolic abnormalities that increase the risk of devel-
oping type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). It can be defined as a 
state of disturbed metabolic homeostasis characterized by the combination of visceral obesity; 
atherogenic dyslipidemia; arterial hypertension and insulin resistance (Grundy 2003). CVD is the 
leading cause of mortality worldwide (Mehra 2007) and the growing prevalence of MS will cer-
tainly contribute to the burden of CVD in the future. Although obesity per se is not a required 
feature for the diagnosis of MS, several evidences suggest that visceral obesity has a key role in 
the pathogenic mechanisms underlying this syndrome (Ribeiro Filho et al. 2006). In order to 
tackle the obesity epidemic, research on adipose tissue (AT) has been gaining momentum. In the 
last years numerous facts have been discovered about this organ, despite many metabolic complex 
pathways remain unknown.  
Since obesity and dyslipidemia are main features of MS and both can present with AT dysfunc-
tion, in this article we revised the effects of the current approved drugs for both dyslipidemia and 
obesity treatments on AT as their underlying mechanisms. 
A methodological assessment of the literature on PubMed and SciELO databases was conducted 
without setting limits for year publication though selecting English, Spanish and Portuguese pa-
pers with full text availability. The following terms were used: adipose tissue; dyslipidemia; fi-
brates; statins; niacin; resins; ezetimibe; obesity;  orlistat; sibutramine; diethylpropion; phenter-
mine/topiramate; bupropion and naltrexone; liraglutide. The retrieved articles until 10/10/2016 
were first selected based on title and abstract. Then, the 145 remaining articles were fully read to 
assess for eligibility and 29 were excluded owing to focus on effects in other organs (liver, pan-
creas, brain) rather  than AT, inadequacy to the theme, being duplicated or full text unavailability. 
The final 116 articles were further analysed. 
1.1 The Adipose Tissue 
AT is nowadays recognized as a major active endocrine organ, secreting several hormones called 
adipokines. Through these hormones, AT has a major role in several physiological systems, such 
as regulation of food intake and body weight, insulin sensitivity, inflammation, coagulation or 
vascular function. These actions are achieved through complex pathways. Adipokines act locally 
within the AT, exerting autocrine and paracrine actions, but also endocrine in distant organs 
through systemic circulation. AT is composed of different cell types, such as mature adipocytes, 
pre-adipocytes, vascular cells and macrophages (Romacho et al. 2014). Adipokines and cytokines 
secreted from these different cells are able to influence each other (Romacho et al. 2014) as a 
variety of organs, being  their balance necessary to maintain health. AT also has the capacity to 
modulate some biological functions, as is the case of those related with cortisol, through the con-
version of cortisone to this corticosteroid by 11β-Hydroxysteroid dehydrogenase type 1 (11β-
HSD1) action (Stimson et al. 2009) (fig. 1.1 B)). The main adipokines produced by adipocytes 
are adiponectin and leptin. Tumour-necrosis factor α (TNFα), interleukin-6 (IL-6), IL-1, CC-
chemokine ligand 2 (CCL2 or MCP-1), Fractalkine, plasminogen-activator inhibitor type 1 (PAI-
1), visfatin and complement factors are also produced by adipocytes, though in lesser extent, and 
mostly by stromal-vascular cells. This interplay is summarized on figure 1.1. 
Adiponectin is the classical anti-inflammatory cytokine. It acts through adiponectin receptor (Ad-
ipoR) 1/2, enhancing the AMP-activated protein kinase (AMPK) pathway. In AT, adiponectin  
acts mainly in macrophages, reducing their phagocytic capacity (Wolf et al. 2004); inducing the 
production of IL-10 and IL-1 receptor antagonist (IL-1RA) (Wolf et al. 2004); supressing the 
production of interferon- γ (IFN-γ) (Wolf et al. 2004) and inhibiting the Toll-like receptors (TLR)-
induced factor nuclear kappa B (NF-κB) pathway activation (Yamaguchi et al. 2005). Although 
8 
 
the differences between the effects of low- (LMW) and high- (HMW) molecular-weight adi-
ponectin still remain unclear, both adiponectin forms induce activation of AMPK pathway and 
suppression of scavenger receptor class B type 1 (SRB1) expression by macrophages (Neumeier 
et al. 2006). Nevertheless, only the LMW form is responsible for inducing IL-10 and suppressing 
IL-6, through peroxisome proliferator-activated receptors (PPARs) stimulation (Neumeier et al. 
2006). In contrast, the HMW adiponectin can even induce the expression of CXC-chemokine 
ligand 8 (CXCL8; also known as IL-8) after an inflammatory stimulation (Neumeier et al. 2006). 
In endothelial cells, it modulates the inflammatory atherosclerosis process, by inhibiting the ex-
pression of adhesion-molecule vascular cell adhesion molecule-1 (VCAM-1), endothelial-leuko-
cyte adhesion molecule-1 (E-selectin), and intracellular adhesion molecule-1 (ICAM-1) induced 
by TNFα (Ouchi et al. 1999). Moreover, it can induce β-oxidation in the liver while decreases the 
expression of sterol regulatory element-binding protein 1 (SREBP1), therefore inhibiting lipogen-
esis. Leptin is, in contrast, a pro-inflammatory cytokine that acts through the leptin receptor 
(OBRb), activating the cyclic adenosine monophosphate (cAMP)-dependent protein kinase A 
(PKA)-extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein ki-
nases (MAPK) pathways (Zhao et al. 2005).  Through these pathways, leptin upregulates the ex-
pression of TNFα, IL-6 and IL-12 in macrophages (Gainsford et al. 1996). It also has a role on 
controlling appetite, angiogenesis, haematopoiesis, neuroendocrine system and immunity (La 
Cava and Matarese 2004). In fact, leptin can regulate neutrophil chemotaxis and natural killer-
cells (NK cells) activity (Tian et al. 2002). It also upregulates inducible nitric-oxide synthase 
(iNOS) expression in AT and, thereby, increases the production of reactive oxygen species (ROS), 
mostly from macrophages (Weisberg et al. 2003; Lumeng et al. 2007). By this mechanism, leptin 
induces macrophage phagocytosis and differentiation of monocytes. TNFα activates TNF recep-
tor (TNFR) which activates the inhibitor of NF-κB kinase-β (IKKβ), in turn, activating the NF-
κB pathway (Yuan et al. 2001). In addition, TNF (and also TLRs stimulation) can also stimulate 
the JUN N-terminal kinase (JNK) family of serine/ threonine protein kinases (Hirosumi et al. 
2002). This latter mechanism is involved in the inhibition of insulin signalling pathway, promot-
ing insulin resistance (Lee et al. 2003), and in insulin sensitivity inhibition as endoplasmic-retic-
ulum (ER) stress leads to the phosphorylation of insulin receptor substrate 1 (IRS1) (Ozcan et al. 
2004). TNFα increases iNOS expression in adipocytes, which appears to supress uncoupling pro-
tein (UCP) 2 expression that could lead to decreasing energy expenditure of white AT (WAT) 
(Merial et al. 2000). Resistin is also a pro-inflammatory cytokine. The production of resistin is 
enhanced by other pro-inflammatory cytokines such as IL-1, IL-6 and TNFα (Kaser et al. 2003). 
Endorsing a positive feedback of inflammation, resistin also increases the expression of IL-1, IL-
6, TNFα and IL-12 upon different types of cells (Silswal et al. 2005; Kaser et al. 2003). This 
inflammatory amplification is driven by adenylyl cyclase-associated protein 1 (CAP1) in mono-
cytes, by which resistin increases cAMP concentration, PKA activity and NF-κB leading thereby 
to upregulation of the aforementioned cytokines (Lee et al. 2014). Moreover, resistin is also able 
to induce the expression of VCAM-1, ICAM-1 and CCL2 in endothelial cells, inducing endo-
thelin-1 (ET-1) secretion (Verma et al. 2003). In this way, resistin contributes to atherosclerosis 
development. MCP-1 is a potent chemoattractant of monocytes and macrophages to AT and acts 
through the CCL2 receptor (CCR2) (Takahashi et al. 2003). Fractalkine (or CX3CL1) and its 
receptor (CX3CR1) are also involved in this process (Shah et al. 2011). PAI-1 is a pro-thrombotic 
agent, inhibitor of plasminogen activators, which expression is induced by TNFα and stress oxi-
dative (Alessi et al. 2007), insulin, glucocorticoids, angiotensin II, fatty acids (FA), TNF-α, and 
TGF-β (Correia and Haynes 2006; Skurk and Hauner 2004). It negatively affects physiological 
metabolism and local vascular biology by interacting with the renin-angiotensin-aldosterone sys-
tem. Moreover, PAI-1 suppresses adipocyte differentiation in adipocytes (Liang et al. 2006). 
Visfatin acts through insulin receptor, although binding to a different site than insulin (Fukuhara 
et al. 2005), acting as a pro-inflammatory cytokine (Chang et al. 2010). It also induces adipocyte 
differentiation (Fukuhara et al. 2005).  
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AT is the main regulator of whole body fat storage, which depends on the balance between energy 
expenditure and intake. In fact, there is a straight modulation between lipid deposition and mobi-
lization though these metabolic pathways are affected by several hormones. Lipid mobilization is 
enhanced in fasting conditions. Likewise, glucagon, catecholamines (through β- adrenoceptors 
(AR)) and atrial or brain natriuretic peptide (ANP/BNP) promote lipolysis (Sengenes et al. 2000). 
In the complex process of lipolysis, after hormonal stimulation, there is an activation of adenylate 
cyclase (AC) enzyme, which activates cAMP-PKA pathway and, consequently, the phosphoryla-
tion of lipases responsible for lipolysis (Lafontan and Langin 2009). The exception for this mech-
anism is for natriuretic peptides (NPs), since they act trough the cyclic guanosine monophosphate 
(cGMP)-dependent protein kinase (PKG) pathway, by activating NPR-A-dependent guanylyl 
cyclase (GC) activity (Moro et al. 2004). These pathways activate three main lipases: adipocyte 
triglyceride (TG) lipase (ATGL), hormone-sensitive lipase (HSL) and monoacylglycerol lipase 
(MGL) (Tsiloulis and Watt 2015). Their sequential action leads to the hydrolysis of TG into di-
glycerides and ultimately into monoglycerides. Also, phosphorylation of perilipin, a lipid droplet-
associated protein, causes its decoupling from lipid droplets, which promotes lipolysis by allow-
ing HSL to gain access to it (Tsoli et al. 2016; Arner and Langin 2014; Krintel et al. 2009). This 
process culminates with the release of FA and glycerol that are uptaken by other tissues (mainly, 
skeletal muscle, liver and heart that use FA for energy production, and liver glycerol in glucone-
ogenesis). On the contrary, insulin and cathecolamines (through α2-AR) inhibit lipid mobilization 
(Sengenes et al. 2000). Insulin inhibits this process through phosphoinositide 3-kinase-dependent 
(PI3-K) pathway, protein kinase B (PKB/Akt), and activation of phosphodiesterase 3B (PDE3B), 
which degradates cAMP. By lowering cAMP levels and by inhibiting adenylyl cyclase (AC) 
through an inhibitory GTP-binding protein (Gi)-coupled receptor, insulin inhibits PKA pathway 
and ultimately lipolysis (Morigny et al. 2016).  
FA β-oxidation is responsible for mitochondrial breakdown of long-chain acyl-CoA to acetyl-
CoA, used for mitochondrial energy production. The PPARs and PPARγ coactivator 1 (PGC-1α) 
are the most well-known transcriptional regulators of FA β-oxidation (Huss and Kelly 2004). 
These regulators enhance the expression of proteins involved in this process such as acyl-CoA 
synthetase (ACS), fatty acid translocase (CD36/FAT), malonyl-CoA decarboxylase (MCD), car-
nitine palmitoyl transferase 1 (CPT-1).  In this context, FAs can undergo the action of ACS and 
CPT1 and thereby be used to β-oxidation.  AMPK phosphorylates PGC-1α protein leading to its 
activation. On the contrary, sirtuin 1 (SIRT1) (a protein deacetylase involved in cellular regulation 
to stress) deacetylates PGC-1α. PGC-1α induces the expression of PPARα, mostly expressed in 
highly metabolic tissues such as liver, heart, skeletal muscle, brown adipose tissue (BAT), en-
hancing the expression of mitochondrial genes and β-oxidation genes (Huss and Kelly 2004). 
Although, it has been settled down that certain stimulus, such as PPAR-α agonists, can cause 
browning of white AT. This process is marked by the expression of PR domain containing 16 
(PRDM16) and PPARγ, and of UCP1 (all markers of BAT), which attributes to WAT a more 
oxidative metabolism (Harms and Seale 2013; Bargut et al. 2017). In lipid mobilization, high-
density lipoproteins (HDLs) are responsible for the reverse cholesterol transport, transporting 
cholesterol from extra-hepatic tissues (including arterial macrophages and AT) to the liver 
(Chapman 2006). These lipoproteins are constituted by cholesterol, triglycerides, phospholipids 
and apolipoproteins A (mainly apoA-I and apo A-II), apo-C and apo-E. The interaction between 
apoA-I and receptors in peripheral tissues, namely ATP binding cassette A1 (ABCA1) transport-
ers and SRB1 are responsible for cholesterol transportation (Chapman 2006). Once filled with 
cholesterol, HDL can deliver the cholesterol into the liver (Chapman 2006).  
Lipid deposition, on the other side, can occur by uptake of circulating FA (in a higher extent) and 
lipogenesis de novo from non-lipid precursors. The former is driven by lipoprotein lipase (LPL), 
secreted by adipocytes, located in the lumen of AT capillaries (Fielding and Frayn 1998). This 
enzyme hydrolysis TG associated to lipoproteins (such as very low-density lipoprotein (VLDL) 
or chylomicrons) into FA, facilitating their uptake by adipocytes (Kersten 2014).  Upon uptake, 
they can suffer reesterification, combining FA with glycerol-3-phosphate (Glycerol-3P), leading 
to TG synthesis (Harris et al. 2011). This process is catalysed by diacylglycerol acyltransferase 
(DGAT) and stimulated by insulin (Harris et al. 2011). Through the lipogenesis de novo process, 
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insulin induces the uptake of glucose by adipocytes (through glucose transporter type 4 (GLUT4)) 
and, through glycolysis, is converted to Acetyl-Coenzyme A. The Acetyl-CoA is converted by 
acetyl-coA carboxylase (ACC) to malonyl-CoA, leading to FA synthesis (Assimacopoulos-
Jeannet et al. 1995). At the same time, insulin inhibits the translocation of FA to mitochondria by 
CPT1 and therefore β-oxidation (Su and Abumrad 2009). The metabolic functions of AT are 
summarized on fig. 1.2. 
Adipogenesis (summarized on fig.1.1 A)) is a tightly regulated cellular differentiation process 
through which preadipocytes are converted into mature adipocytes. It is essential to the renewing 
of AT and to the modulation of fat deposition process. Adipogenesis comprises two phases: 1) 
the commitment of pluripotent stem cell to a unipotent preadipocyte and 2) differentiation of 
preadipocytes into mature adipocytes (fig. 1.1 A)). In the first phase, bone morphogenetic proteins 
(BMPs) and TAK1 pathways are involved, whereas in the second terminal differentiation phase, 
other transcription factors such as PPARγ, CCATT enhancer-binding proteins (C/EBP) and 
SREBP1 take action (Kim and Spiegelman 1996). After hormonal stimulation, there is an increase 
in intracellular cAMP, leading to transcription of C/EBPβ and C/EBPδ in preadipocytes, which 
translocate to the nucleus and enhance the expression of C/EBPα and PPARγ (Roesler et al. 1998). 
PPARγ heterodimerizes with retinoid X receptor-α (RXRα) and bind to DNA, promoting tran-
scription of the adipocyte-specific genes,  leptin, adiponectin, fatty acid-binding protein-4 
(FABP4) and perilipin (Rosen et al. 2000). In addition, C/EBPα also enhances the transcription 
of leptin and FABP4, as well as other genes, such as GLUT4 and stearoyl-coA desaturase-1 
(SCD1) (Guo et al. 2015). During differentiation, SREBP1 is activated and translocated to the 
nucleus, where it binds to sterol response elements (SRE) and induces the expression of lipogenic 
enzymes such as ACC, fatty acid synthase (FAS), LPL, and SCD1 (Kim and Spiegelman 1996; 
Alvarez et al. 2014). 
1.2 Obesity and dyslipidemia: two disorders walking together 
Obesity and dyslipidemia are two main features of MS. Dyslipidemia refers to a range of lipid 
profile disorders, resulting from quantitative (higher or lower lipid or/and lipoprotein levels) or 
qualitative alterations (structural alterations in lipoprotein molecules) (Brunzell JD 2010). In 
respect to aetiology, these disorders are classified as primary, in which exists a primary disorder 
of lipid metabolism, and secondary. This last type, the most common (80%), is a consequence of 
medical conditions such as T2DM and obesity, unhealthy  lifestyle habits, mainly excessive 
alcohol consumption and cigarette smoking and the use of some drugs (Eaton 2005; Brunzell 
2007; Jellinger et al. 2017). Dyslipidemia is a primary, major risk factor for CVD (Jellinger et al. 
2017). Obesity is a multifactorial disease, characterised by a local and systemic chronic low-grade 
inflammation state causing metabolic abnormalities and adipocyte dysfunction (Curat et al. 2004), 
that ultimately lead to CVD. This state has also been implicated in the development of obesity-
related complications such as insulin resistance, T2DM, arterial hypertension, dyslipidemia and 
cancer (Ng et al. 2014). The growing MS prevalence seems to be closely related to the obesity 
epidemic (Heinl et al. 2016). Additionally, obesity also seems to be associated with the rising 
prevalence of dyslipidemia, as studies have suggested a positive correlation between body mass 
index (BMI) and dyslipidemia (Cohen et al. 2010; Lamon-Fava et al. 1996). 
Obesity, mainly hypertrophy, is characterized by AT dysregulation (Gustafson et al. 2013). 
Eventually, this dysfunctional AT can cause dyslipidemia. It is known that dysfunctional 
adipocytes become insulin resistant, favouring lipolysis. This is due to an increase in HSL activity, 
releasing FFA, cytokines and adipokines (Sun et al. 2011; Despres and Lemieux 2006; Hyun et 
al. 2008). FFA not oxidized for fuel, are uptaken by liver, increasing intrahepatic fat and causing 
liver steatosis (Fabbrini et al. 2009; Fabbrini et al. 2008). The removal of intrahepatic TG occurs 
within the VLDL-TG; and rate of hepatic VLDL-TG secretion seems to be greater in subjects 
with high intra-hepatic TG content (Fabbrini et al. 2009), thus the more intra-hepatic fat, the more 
the VLDL-TG turnover. FFA, but also insulin resistance (Panarotto et al. 2002) and inflammation 
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(Kawakami et al. 1987), cause a decrease in LPL expression and activity, leading to an increase 
in circulating TG (VLDL-TG and chylomicrons). Body fat accumulation also seems to enhance 
cholesteryl ester transfer protein (CEPT) activity causing a decrease in HDL levels (Arai et al. 
1994). In fact, the simultaneous increase of TG and decrease of HDL (Castelli 1998) constitutes 
the atherogenic dyslipidemia pattern most common in obese individuals (Poirier et al. 2006). 
Hiperleptinemia is present in obesity, and leptin, through enhancement of hepatocyte nuclear 
factor 1 homeobox A expression (which binds to proprotein convertase subtilisin/kexin type 9 
(PCSK9) promotor and MAPK pathway) seems to be able to upregulate the expression of PCSK9, 
thereby inhibiting the expression of low density lipoprotein (LDL) receptors and, consequently, 
LDL uptake in hepatocytes (Du et al. 2016). Thus, hyperleptinemia alone, by increasing LDL 
levels, can contribute to the development of CVD associated to obesity (Du et al. 2016). Globally, 
when obesity is associated with AT dysfunction, ectopic fat accumulation, especially in liver, and 
inflammation, it favours the development of dyslipidemia (Fon Tacer and Rozman 2011). 
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2 Drugs used in dyslipidemia 
2.1 HMG-CoA reductase inhibitors (Statins) 
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as 
statins, act by inhibiting in a competitive manner the rate-limiting step of cholesterol synthesis in 
liver, namely the conversion of HMG-CoA to mevalonic acid. Statins increase LDL receptors 
expression in liver, which in turn increases LDL catabolism and lowers total cholesterol concen-
tration. Their metabolic effect includes a LDL reduction of 21-55%, a TG reduction of 6%-30% 
and an increase in HDL of 2%-10%. New-onset diabetes may be increased in patients treated with 
statins; however, it is dose-related and seems to be less common with pravastatin and possibly 
pitavastatin (Jellinger et al. 2017). Increasing evidence has shown that there is much more to 
reveal about this drug. 
2.1.1 Effects upon adipocyte metabolic functions 
AT acts as a buffer of plasmatic cholesterol and statins have an important role decreasing basal 
cholesterol release (Bencharif et al. 2010) and content (Krautbauer et al. 2013) in adipocytes. In 
fact, they are capable of reverting basal cholesterol release from adipocytes, though not after apo-
A-I stimulation (inducing cholesterol release and apo-E secretion by adipocytes) (Bencharif et al. 
2010). In mature adipocytes, pitavastatin upregulates HSL expression, enhancing lipolysis, de-
creasing lipid accumulation and preventing adipocyte hypertrophy, and increasing the number of 
small adipocytes (Ishihara et al. 2010). Intensive treatment with atorvastatin also leads to the 
regression of epicardial AT volume (Alexopoulos et al. 2013). Statins seem to induce mRNA LPL 
expression in preadipocytes (Bey et al. 2002; Saiki et al. 2006) as well as enhance lipoprotein 
lipase (LPL) activity in 3T3-L1 pre-adipocytes (Bey et al. 2002) and adipocytes (Saiki et al. 
2006). The underlying mechanism involves different transcription factors, such as SREBP or 
PPARγ (Bey et al. 2002). These effects contribute to lower triglyceride and VLDL levels (Bey et 
al. 2002; Saiki et al. 2006). In contrast, it has been shown that in a bone marrow stromal cells 
model, statins can reduce LPL mRNA expression (Song et al. 2003). 
Although the enhancement of LPL activity seems to be a common effect of this class, different 
statins have shown divergent effects on LPL expression in adipocytes. Authors refer the following 
mechanisms to explain this: 1. different affinities to adipocytes due to statins hydrophilic propri-
eties; 2. drug metabolites such as pro-drugs; and finally, 3. existence of different tissues express-
ing LPL that could interfere with the in vivo effect. Moreover, authors suggest that these differ-
ential effects could be due to a direct or indirect effect, respectively, upon LPL expression and/or 
upon HDL levels and LDL size (Saiki et al. 2006).  
 
2.1.2 Effects upon inflammation 
Many studies support an anti-inflammatory effect of statins in AT. After exposure to a stressful 
and inflammatory stimulus, the expression of pro-inflammatory adipokines and cytokines, such 
as Leptin (Krysiak et al. 2014c; Labuzek et al. 2011; Maeda and Horiuchi 2009; Zhao and Wu 
2005; Krysiak et al. 2014d), Resistin (Ichida et al. 2006; Labuzek et al. 2011; Li et al. 2016), IL-
6 (Labuzek et al. 2011; Zhao and Zhang 2003; Dobashi et al. 2008; Yin et al. 2007; Wang et al. 
2014; Abe et al. 2008), Plasminogen activator inhibitor-1 (PAI-1) (Laumen et al. 2008; Lobo et 
al. 2012; Sakamoto et al. 2011), MCP-1 (Lobo et al. 2012; Wu et al. 2013; Wang et al. 2014; 
Takagi et al. 2008; Abe et al. 2008), Visfatin (Krysiak et al. 2014d) and TNF-α (Krysiak et al. 
2014c; Labuzek et al. 2011; Wu et al. 2013; Wang et al. 2014; Krysiak et al. 2014d; Takagi et al. 
2008)  increases. Statins can reduce pro-inflammatory cytokines and adipokines expression 
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(Ichida et al. 2006; Labuzek et al. 2011; Laumen et al. 2008; Lobo et al. 2012; Maeda and Hori-
uchi 2009; Sakamoto et al. 2011; Zhao and Zhang 2003; Dobashi et al. 2008; Yin et al. 2007; 
Zhao and Wu 2005; Wu et al. 2013; Krysiak et al. 2014d; Li et al. 2016; Wang et al. 2014; Krysiak 
et al. 2014c; Ishihara et al. 2010), while enhancing anti-inflammatory adipokines expression and 
secretion by adipocytes (Labuzek et al. 2011; Lobo et al. 2012; Yin et al. 2007; Ishihara et al. 
2010; Li et al. 2016; Krysiak et al. 2014c). For instance, by upregulating PPARγ expression in 
adipocytes, statins decrease IL-6 expression and plasma concentration (Zhao and Zhang 2003).  
Moreover, these drugs can decrease high sensitivity C-reactive protein (CRP) plasma levels (Kry-
siak et al. 2014c). In addition, the combination of two drugs, statins and fibrates, has evidenced a 
higher reduction in pro-inflammatory cytokines secretion (Labuzek et al. 2011).  The combination 
of Ezetimibe-simvastatin treatment, as opposed to simvastatin treatment in monotherapy, demon-
strated a higher effect in reducing pro-inflammatory adipokines and increasing adiponectin levels 
(Krysiak et al. 2014d). This suggests a direct modulation of both production and secretion of these 
adipokines (Krysiak et al. 2014d) and these effects were more prominent in insulin resistant indi-
viduals (Krysiak et al. 2014d). In addition to an anti-inflammatory effect, it seems that cholesterol-
lowering effect of statins can contribute to inhibit ER stress (Wu et al. 2013).  Statins inhibit leptin 
expression due to alterations in RNA processing that reduce heterogeneous nuclear RNA abun-
dance (Maeda and Horiuchi 2009). Moreover, statins inhibit PI3K pathway through protein 
prenylation suppression. This allows the activation of PKA and, consequently, suppression of 
leptin expression in 3T3-L1 cells. A reduced mRNA C/EBPα expression seems to be partially 
involved in this last effect, which emphasises the importance of leptin expression to regulate ad-
ipocyte differentiation (Maeda and Horiuchi 2009).  As IL-6 is able to raise leptin levels, statins, 
by reducing IL-6 levels, can also reduce leptin levels (Zhao and Wu 2005). Statins also reduce 
the expression of resistin in human monocyte/macrophages in vitro as well as in 3T3-L1 adipo-
cytes, supporting their anti-inflammatory role (Wu et al. 2013; Li et al. 2016). However, atorvas-
tatin treatment in vivo for 6 months did not significantly reduced serum resistin levels (Wu et al. 
2013). Statins appear to inhibit the PAI-1 promoter activity, through mitogen-activated protein 
kinase kinase Kinase 1 (MEKK1) and, in a lesser extent, NFκB. Since isoprenoids, such as 
geranylgeranyl pyrophosphate and farnesylpyrophosphate, were able to revert rosuvastatin effect 
in PAI-1 expression, proteins geranylation or/and farnesylation could be the involved mechanisms 
(Maeda and Horiuchi 2009). In animal studies, statins are able to decrease inflammation in per-
icarotidal AT from high fat diet (HFD) treated mice (Wang et al. 2014) and in WAT of hypercho-
lesterolemic pigs (Busnelli et al. 2013). This effect is achieved by downregulation of 5-lipoxy-
genase, decreased macrophagic infiltration (Wang et al. 2014) and downregulation of pro-
inflammatory adipokines/cytokines (Wang et al. 2014). In hypercholesterolemic pigs WAT, 
statins also prevent adipocyte hypertrophy and diminish T lymphocyte infiltration (Busnelli et al. 
2013). Statins can partially contain AT inflammation in obese mice (Abe et al. 2008), through 
downregulation of mRNA MCP-1 and IL-6 expression (Abe et al. 2008) and also through inhibi-
tion of TLR4-induced expression of interferon gamma in macrophages (Abe et al. 2008). 
Statins have different roles in the regulation of iNOS according to cell type. In 3T3-L1 preadipo-
cytes, statins inhibit NO production after inflammatory exposure. This effect is mediated by 
NFκB pathway inhibition, reducing iNOS mRNA expression (Dobashi et al. 2008). In contrast, 
in 3T3-L1 mature adipocytes, statins enhance iNOS expression, increasing NO levels (Araki et 
al. 2007). This effect is dependent on the type of statin (Araki et al. 2007) and the underlying 
mechanism seems to be NFκB activation, which contributes to up-regulation of iNOS gene and, 
ultimately, to a higher NO production (Araki et al. 2007). Moreover, NFκB activation is achieved 
through diminishing metabolites of cholesterol synthesis, such as isoprenoid and small G proteins 
(Araki et al. 2007). 
2.1.3 Effects upon atherogenesis 
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Atherogenesis is a degenerative process in which arteries walls become occupied with excess and 
modified lipids in circulation (Singh et al. 2002). It involves adhesion of monocytes and lympho-
cytes to the endothelial cell surface; migration of monocytes into the sub-endothelial space and 
differentiation into macrophages; ingestion of LDL and modified or oxidized LDL (ox-LDL) by 
macrophages, leading to accumulation of cholesterol esters and formation of "foam cells”. More-
over, vascular smooth muscle cells migrate from the media into the intima and proliferate occur-
ring the formation of atherosclerotic plaques (Ross and Agius 1992). Macrophages phagocytosis 
of ox-LDL is mediated by SRB1 (Singh et al. 2002). Adipocytes can also uptake ox-LDL, a mech-
anism positively correlated with PPARγ and SRB1 expression and negatively with LDL concen-
tration (Zhao and Zhang 2004; Breen et al. 2012). Statins are able to induce PPARγ and SRB1 
expression in adipocytes (Zhao et al. 2006; Zhao and Zhang 2004). Despite not fully understood, 
this suggests both indirect, through lowering cholesterol, and direct effects, possibly through 
SRB1 stimulation (Zhao et al. 2006). Moreover, as statins reduce lipid accumulation in adipocytes 
(Ishihara et al. 2010), there is a disinhibition of PPARγ expression that per se could enhance the 
ox-LDL uptake by adipocytes (Zhao et al. 2006).  
By decreasing the expression of pro-inflammatory and increasing anti-inflammatory adipokines 
statins have a fundamental role in inflammatory related-processes, such as atherosclerosis (Kry-
siak et al. 2014c; Li et al. 2016), with the recent evidence supporting an anti-atherogenic effect of 
these drugs.  
2.1.4 Effects upon insulin sensitivity 
Recently, evidence on the association between insulin resistance, T2DM de novo and statin treat-
ment has been increasing.  Caveolae are plasma membrane microdomains, composed by choles-
terol, sphingolipids, and different coat proteins named caveolins, considered anchor points to 
molecules (i.e. in this context, insulin receptor and GLUT4), facilitating their interaction, in order 
to activate cell signalling and transport (Cohen et al. 2003; Liu et al. 2008; Chidlow and Sessa 
2010).  
Caveolins are modulated by cavins and cavin-2 is pointed out as a cholesterol-dependent protein 
essential to define caveolar structure (Breen et al. 2012). Through cholesterol depletion, statins 
cause caveolae collapse in adipocytes inducing proteasomal degradation of cavin-2 and redistri-
bution of cavin-1 to the cytosol (Breen et al. 2012). Taking into account the importance of cave-
olae in insulin signalling pathways in adipocytes (Cohen et al. 2003; Liu et al. 2008), evidence 
show that insulin resistance is due, at least partially, to caveolae dysfunction. Moreover, statins 
disruption of caveolar formation seems to reduce HMW adiponectin secretion by adipocytes 
(Krautbauer et al. 2013), a mechanism that can reduce insulin sensitivity. Lipophilic statins can 
also induce structural alterations in GLUTs (Nowis et al. 2014) and impair GLUT4 protein ex-
pression (Ganesan and Ito 2013), leading to inhibition of GLUT4 translocation and, consequently, 
decreasing insulin-stimulated glucose uptake in 3T3-L1 adipocytes (Takaguri et al. 2008). How-
ever, co-treatment with coenzyme Q10, an endogenous cellular antioxidant, seems to attenuate 
this effect (Ganesan and Ito 2013). Although being a lipophilic statin, atorvastatin can improve 
insulin sensitivity in an obese mice model (Poletto et al. 2015), through an increase in mRNA and 
protein expression of slc2a4 gene (which codifies GLUT4) and a decrease in mRNA and protein 
expression of IL6 in subcutaneous AT (SCAT) (Poletto et al. 2015). Authors also suggest a pos-
sible role of IKK/NFκB pathway in these effects (Poletto et al. 2015). On the other hand, hydro-
philic statins generally improve insulin sensitivity, even in HFD-induced overweight mice, with 
no changes in body weight, AT mass or adipocyte size (de las Heras et al. 2013; Valero-Munoz 
et al. 2014). These statins also increase PPARy and GLUT4 expression and reduce leptin expres-
sion in AT (de las Heras et al. 2013; Valero-Munoz et al. 2014). Hydrophilic statins augment 
basal and insulin-stimulated glucose uptake in AT (Salunkhe et al. 2016; Takagi et al. 2008), thus 
decreasing hyperglicemia. 
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2.1.5 Effects upon adipogenesis 
Statins are responsible for inhibiting preadipocytes differentiation through downregulation of 
PPARγ2 and 422aP. Instead, they induce upregulation of RunX2/Cfbal, promoting osteoblastic 
differentiation (Zhang et al. 2013). In fact, it has been shown that statins stimulate osteoblastic 
differentiation, proliferation, maturation and synthesis of new bone (Pengde et al. 2008; Song et 
al. 2003; Zhang et al. 2013). Moreover, statins also inhibit adipogenesis through a reduction in 
LPL mRNA expression (Song et al. 2003). In a 3T3-F442A cell model, statins have shown a 
higher sensitivity to inhibit adipocyte differentiation comparing to 3T3-L1 cells (Elfakhani et al. 
2014). However, pitavastatin does not affect the preadipocyte differentiation/maturation in vitro 
(Ishihara et al. 2010). Mevastatin in turn, inhibits orbital preadipocytes differentiation through 
blockage of PPARγ expression (Yi and Xu 2010).  In the early phase of adipogenesis, statins seem 
to induce a phenotype change leading to 3T3-L1 cells rounding-up at 6h and their detachment at 
48h after the onset of differentiation (Tomiyama et al. 1999), an effect not observed in the late 
phase of adipogenesis (Tomiyama et al. 1999). Statins downregulate the expression of crucial 
genes to adipocyte differentiation including C/EBPα, PPARγ and SREBP-1 and maturation mark-
ers such as leptin, FABP4 and adiponectin (Elfakhani et al. 2014). An inhibitory effect of PI3K 
can also be an underlying mechanism for this effect (Tomiyama et al. 1999). Moreover, Tomi-
yama et al. mentioned a possible contribution of isoprenoids synthesis and Ras-Raf1-MAPK path-
way inhibition (Tomiyama et al. 1999). More recently, it was reported that statins, by reducing 
mevalonate-derived non-sterols isoprenoids (intermediate metabolites of cholesterol biosynthe-
sis, crucial to adipocyte differentiation (Chamberlain 2001)), can cause a compensatory upregu-
lation of HMG-CoA reductase (Elfakhani et al. 2014). Despite these results, in vivo studies have 
shown that statins stimulate adipocyte differentiation (Khan et al. 2009; Phillips et al. 2001), 
which evidences the complex mechanism that underlie AT proliferation and differentiation. 
 
2.2 Fibric acid derivatives (Fibrates) 
The most pronounced effects of fibrates are the decrease in plasma TG-rich lipoproteins (Staels 
et al. 1998). In one hand, they increase lipoprotein lipolysis, but on the other, they increase FFA 
hepatic uptake and reduce hepatic TG production (Rosenson 2017), achieving TG reductions of 
35 to 50%. Fibrates also increase HDL cholesterol in 5-20%, due to an increase in apo-A-I and 
apo-A-II production in liver, which may contribute to a more efficient reverse cholesterol 
transport (Rosenson 2017) and trough the activation of PPARα (Derosa et al. 2017). LDL choles-
terol generally decreases in individuals with elevated baseline plasma concentrations (Staels et al. 
1998), with reductions of 20-25% (Jellinger et al. 2017). Fibrates convert small cholesterol-de-
pleted LDL particles to large-cholesterol-enriched LDL particles. By shifting LDL particles to a 
larger size, these particles are removed from circulation more efficiently (Rosenson 2017) thus 
improving the atherogenic profile (Jellinger et al. 2017). Fibrates are synthetic ligands of PPARα 
(Yan et al. 2014), acting by peroxisome proliferators response element (PPRE) stimulation, whose 
activation leads to increased hepatic β-oxidation of FA, reduced hepatic TG secretion and in-
creased LPL activity and consequent VLDL clearance (Derosa et al. 2017). Gemfibrozil, how-
ever, may increase LDL levels in 10%-15% (Jellinger et al. 2017). Despite these clinical similar-
ities, fibrates may have a different spectrum of effects upon AT.  
2.2.1 Effects upon adipocyte metabolic functions 
Bezafibrate, a non-selective PPAR (α, δ/β, γ) agonist, regulates energetic homeostasis by upreg-
ulation PPARα and UCP1, 2 and 3 (Cabrero et al. 2001; Vazquez et al. 2001). It induces mRNA 
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acyl-CoA oxidase (ACO) expression which stimulates FA oxidation in mitochondria and peroxi-
somes of adipocytes (Cabrero et al. 2001; Vazquez et al. 2001; Goto et al. 2011). The oxidative 
rate is higher in preadipocytes than in mature adipocytes (Cabrero et al. 2001). Moreover, as FA 
concentrations reduce, it also inhibits lipogenesis (Cabrero et al. 2001).  
On the contrary, gemfibrozil, a PPARα agonist, induces a fast increase in TG synthesis in both 
preadipocytes and adipocytes (Baldo et al. 1994). Gemfibrozil improves their capacity for subtract 
uptake (glucose and oleate) and enhances activity of enzymes needed for this synthesis (Baldo et 
al. 1994). By increasing FA uptake and TG synthesis in peripheral tissues, gemfibrozil decrease 
FA plasma concentration, which  enhances extracellular hydrolysis by LPL present in endothelial 
cells (Baldo et al. 1994).  
Fenofibrate, another PPARα agonist, is able to decrease body mass independently of food intake 
(Rachid et al. 2015b) and to reduce visceral AT (VAT) mass (Elfakhani et al. 2014) through 
PPARα stimulation and upregulation of FA oxidation enzymes in AT, such as CPT-1 (Gonzalez 
et al. 2009; Ferreira et al. 2014) and ACO (Ferreira et al. 2014). It also increases the number of 
small, in detriment of large, adipocytes in diet-induced obese and insulin resistant mice (Elfakhani 
et al. 2014). Fenofibrate can increase energy expenditure in diet-induced obese mice (Rachid et 
al. 2015b), since it seems to upregulate, through PPARα pathway, thermogenesis-related genes 
such as UCP-1, PRDM16, PGC-1α, nuclear respiratory factor 1 and mitochondrial transcription 
factor A) (Rachid et al. 2015b, a). Moreover, increasing PGC-1α expression, fenofibrate increases 
irisin levels, which enhances UCP-1 expression (Rachid et al. 2015a). Through this mechanism, 
in SCAT, fenofibrate induces the browning of adipocytes of WAT, converting them in beige ad-
ipocytes (having a higher basal metabolic rate) (Rachid et al. 2015a). Fenofibrate decreases up-
take of FA in AT due a reduced LPL activity (Ferreira et al. 2006) and by increasing HSL activity 
(Brandes et al. 1986), decreases lipogenesis and increases lipolysis (Ferreira et al. 2006).  
On the other hand, fenofibrate was also described to increase adiposity in epididymal, liver and 
kidneys AT in an insulin resistant and hypertriglyceridemic rat model (Sedova et al. 2004). In 
humans, fenofibrate treatment has been shown to increase liver TG synthesis, through PPARα, 
leading to hepatic steatosis (Yan et al. 2014). 
Most of the evidence suggest that fibrates, by decreasing body weight (Chen et al. 2014; Vazquez 
et al. 2001; Jeong and Yoon 2009; Gonzalez et al. 2009; Ferreira et al. 2014; Rachid et al. 2015b, 
a), reduce plasma leptin concentration thus increasing caloric intake (Vazquez et al. 2001). Dif-
ferent experimental models and fibrates might explain these opposite effects.  
2.2.2 Effects upon inflammation 
Fenofibrate enhances adiponectin (Labuzek et al. 2011; Oki et al. 2007) (HMW form in hypertri-
glyceridemic patients (Oki et al. 2007)) and vaspin expression and secretion (by PPRE, with a 
stronger contribution of PPARα than PPARy) (Chen et al. 2014), and, when in high concentra-
tions, diminishes MCP-1 (Toyoda et al. 2008) and TNFα secretion (Labuzek et al. 2011; Toyoda 
et al. 2008; Zhao and Wu 2004; Jeong and Yoon 2009). In a co-culture model of 3T3-L1 adipo-
cytes and RAW264 macrophages, TNFα lowering effect was related to the inhibition of NF-kB 
pathway (Toyoda et al. 2008), although with no changes in both macrophage infiltration and li-
polysis (Toyoda et al. 2008).  
In an obesogenic environment, AdipoR1 and 2 protein expression in VAT is diminished (Bauer 
et al. 2010), supporting the notion that VAT is more prone to inflammatory processes. Feno-
fibrate, however, upregulates AdipoR2 expression in 3T3-L1 adipocytes (Bauer et al. 2010) and, 
when combined with statins, lowers others pro-inflammatory cytokines secreted by adipocytes 
(Labuzek et al. 2011). Furthermore, bezafibrate also downregulates PPARγ and TNFα expression 
while upregulates FABP4 (Cabrero et al. 2001) and adiponectin expression (partially through 
PPARα, enhancing the PPRE site located in adiponectin promoter) in adipocytes (Nakano et al. 
2007; Hiuge et al. 2007). In contrast with other species, in human adipocytes, visfatin seems not 
to be regulated by fenofibrate (Oki et al. 2007).  
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In TNFα stimulated-adipocytes, fenofibrate activates AMPK pathway, up-regulating the 
expression of SIRT1 (Wang et al. 2013), thus inducing NF-kBp65 deacetylation, which inhibits 
adipocyte cluster of differentiation 40 (CD40) expression (a costimulatory protein present in 
antigen presenting cells, essential for their activation in inflammatory pathways), impairing the 
obesity-related low-grade chronic inflammation state (Wang et al. 2013).  
Bezafibrate lowers 11β-hydroxysteroid dehydrogenase type 1 mRNA expression in AT and liver 
(Nakano et al. 2007) and its activity in adipocytes (Nakano et al. 2007). 
Aldehyde oxidase 1 (AOX1) is an enzyme responsible for drugs catabolism and activation (Wei-
gert et al. 2008), producing ROS. ROS are related to obesity-induced insulin resistance, impair-
ment of adipogenesis, decrease of lipid storage in WAT and release of adiponectin (Weigert et al. 
2008). Although mainly expressed in liver, it is also expressed in mature adipocytes, mainly in 
VAT (Weigert et al. 2008). Fenofibrate, partially by PPARα stimulation, reduces protein AOX1 
expression (Weigert et al. 2008) leading to both antioxidant and anti-inflammatory effects (Wei-
gert et al. 2008). 
2.2.3 Effects upon atherogenesis 
Fenofibrate ameliorates uptake and degradation of oxLDL, thus potentiating oxLDL blood clear-
ance by adipocytes (Zhao et al. 2004). Moreover, fenofibrate by downregulation of PPARγ ex-
pression and upregulation of SRB1 expression in AT (Zhao et al. 2004), increases oxLDL both 
uptake and degradation by adipocytes (Zhao et al. 2004). Globally, fibrates seem to reduce adi-
posity and atherogenesis, despite the complex underlying molecular mechanisms remain partially 
unknown (Zhao and Wu 2004; Zhao et al. 2004; Ferreira et al. 2014).  
 
2.2.4 Effects upon insulin sensitivity 
Fenofibrate can improve insulin sensitivity and glucose tolerance, even in insulin resistant mod-
els. It increases basal and insulin-stimulated glucose uptake by adipocytes (Ferreira et al. 2014) 
and lowers plasma FFA, TG, insulin and glucose concentrations (Jeong and Yoon 2009; Rachid 
et al. 2015a). Besides lowering TNFα expression, fenofibrate also decreases leptin expression 
(Jeong and Yoon 2009; Rachid et al. 2015a) causing insulin secretion in the postprandial period 
(Rachid et al. 2015a). Fibrates upregulate phosphoenolpyruvate carboxykinase expression in ad-
ipocytes (independently of protein synthesis) (Glorian et al. 1998) retaining FA output from AT 
to bloodstream (Glorian et al. 1998; Sedova et al. 2004). 
2.2.5 Effects upon adipogenesis 
Through direct binding to PPARα, fibrates induce adipogenesis (Goto et al. 2011), increasing the 
activity of enzymes involved in FA synthesis, and leading to lipid accumulation in small and 
numerous droplets in adipocytes (Verrando et al. 1981; Brandes et al. 1986; Baldo et al. 1994). 
In orbital fibroblasts, fibrates also upregulate mRNA and protein expression of non-histone chro-
mosomal high mobility group AT-hook 2, leptin and functional TSH receptor inducing preadipo-
cyte differentiation (Pasquali et al. 2004).  
Furthermore, fibrates reduce LPL activity, which suggests that they could rise serum lipoproteins 
concentration that can serve as substrates to TG storage in adipocytes (Brandes et al. 1986).  
Summing up, fibrates have an important role in metabolism and inflammation control and in ad-
ipogenesis modulation. Fibrates can improve obesity-related mitochondrial metabolic dysfunc-
tion and chronic low-grade inflammation as insulin resistance (Nakano et al. 2007; Chen et al. 
2014; Labuzek et al. 2011; Oki et al. 2007; Toyoda et al. 2008; Jeong and Yoon 2009; Sedova et 
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al. 2004; Zhao and Wu 2004; Bauer et al. 2010; Glorian et al. 1998; Hiuge et al. 2007; Wang et 
al. 2013; Weigert et al. 2008). 
2.3 Niacin (nicotinic acid) 
Niacin is one of the most effective agents currently available capable of increasing HDL levels 
(Garg et al. 2017). It acts inhibiting hepatocyte HDL-apo A-I holoparticle receptor, responsible 
for HDL catabolism. Moreover, studies have demonstrated that niacin increases PPARγ 
expression, through macrophage ABCA1, which affects reverse cholesterol transport (Kamanna 
and Kashyap 2008). Niacin also affects the remaining lipid profile, decreasing total cholesterol, 
LDL, TG, and lipoprotein (a) levels (Garg et al. 2017; Zhao et al. 2008). Niacin is able to decrease 
TG synthesis and its availability for VLDL assembly, resulting in increased posttranslational 
intrahepatic apo-B degradation, thus decreasing plasma TG and liver secretion of apo-B–
containing lipoproteins, including VLDL and LDL particles (Kamanna and Kashyap 2008). In 
respect to deleterious effects, it is known that niacin, at high dosages, increases uric acid levels 
and can aggravate glucose levels (Jellinger et al. 2017). Niacin is used in high doses in refractory 
dyslipidaemia treatment despite its limited use due to poor tolerability (mostly due to flushing, 
hepatotoxicity, myopathies (Probstfield and Hunninghake 1994; Etchason et al. 1991)). 
2.3.1 Effects upon adipocyte metabolic functions 
Niacin, through HM74a receptor (coupled to Gi/o proteins (Karpe and Frayn 2004)), reduces ba-
sal (Zhao et al. 2008; Zhang et al. 2005; Plaisance et al. 2009) and noradrenaline (NA)-induced 
release of plasma FFAs (Carlson 1963) and inhibits lipolysis (Carlson 1963; Plaisance et al. 2009; 
Zhang et al. 2005). 
Chronic treatment with niacin was shown to decrease plasma FFAs levels, although a rebound 
effect can occur (Oh et al. 2011). A prolonged treatment enhances β-AR responsivity via post-
receptor signalling alterations (Heemskerk et al. 2014b; Oh et al. 2011). Moreover, niacin also 
decreases the expression of genes involved in TG synthesis and FFAs reesterification, leading to 
an increase in lipolysis (Oh et al. 2011). Additionally, a decrease in perilipin and adipose phos-
pholipase A2 protein expression could also contribute to FFAs rebound (Oh et al. 2011). 
A long term niacin treatment increases n-3 polyunsaturated fatty acids (PUFAs) synthesis in AT, 
but not in liver (Heemskerk et al. 2014a), thus suggesting that the main source of n-3 PUFAs is 
AT, through lipolysis (Heemskerk et al. 2014a). In this regard, niacin leads to upregulation of 
unsaturated FA biosynthesis genes (Elovl6, Elovl5, Tecr) in hyperlipidemic mice, thus increasing 
the elongation, but not desaturation of FA (Heemskerk et al. 2014a). Although prolonged niacin 
treatment enhances plasma n-3 PUFAs levels, it does not alter significantly arachidonic acid-
derived proinflammatory oxylipins (Heemskerk et al. 2014a). In addition, n-3 PUFAs compete 
directly with n-6 PUFAs, contributing to CV protection (Heemskerk et al. 2014a). 
 
2.3.2 Effects upon inflammation 
Niacin directly decreases the TNFα-induced inflammatory profile of AT. It reduces MCP1, 
RANTES, Fractalkine (all involved in macrophage and T cells inflammatory recruitment) gene 
and protein expression, thus inhibiting macrophage chemotaxis (Digby et al. 2010). It also de-
creases TNFα-induced iNOS gene expression, which lowers ROS synthesis (Digby et al. 2010). 
In contrast, in adipocytes, niacin increases adiponectin gene expression though not affecting its 
secretion (Digby et al. 2010).  
Binding of niacin to HM74a receptor, after either acute or chronic exposure, increases adiponectin 
secretion (total and HMW forms), even in adipocytes from MS patients (Plaisance et al. 2009). 
In these patients, acute treatment with niacin decreases plasma NEFAs concentrations (without 
an effect upon both resistin and leptin concentrations) (Plaisance et al. 2009). However, chronic 
niacin treatment increases leptin levels even without changing other adipokines (Westphal et al. 
2007). 
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2.3.3 Effects upon atherogenesis 
Niacin enhances cholesterol efflux rate in adipocytes through, at least partly, the PPARγ activa-
tion and, consequently, LXRα (liver X receptor alpha, an essential transcriptional factor for me-
tabolism and transport of cholesterol in peripheral tissues) and ABCA1 transporter expression 
(Wu and Zhao 2009; Zhao et al. 2008).  Through this mechanism, niacin treatment could increase 
HDL-induced cholesterol efflux from adipocytes and plasma HDL levels (Wu and Zhao 2009; 
Zhao et al. 2008). The mechanism involved in overexpression of these factors is unclear, although 
a role of HM74a as the initial trigger has been pointed out (Zhao et al. 2008).  
Niacin stimulates PPARγ expression and activity increasing anti-inflammatory prostaglandin syn-
thesis and secretion by macrophages (Knowles et al. 2006).  
Nevertheless, prolonged treatment with niacin seems not to change endothelial function and in-
flammatory activity in MS patients (Westphal et al. 2007). 
 
2.3.4 Effects upon insulin sensitivity 
Prolonged treatment with niacin seems to induce insulin resistance (Westphal et al. 2007; 
Heemskerk et al. 2014b). In fact, in dyslipidemic mouse models, niacin downregulates genes in-
volved in insulin (such as INSR and PDE3B) and β-adrenergic (such as β-1,2,3-AR) signalling 
pathways (Heemskerk et al. 2014b), whereas prolonged treatment enhances β-AR responsivity 
(Heemskerk et al. 2014b; Oh et al. 2011). The authors suggest that the duration needed to increase 
adiponectin levels could be counterbalanced by other adverse effects, such as, a rebound increase 
in plasma FFAs (Westphal et al. 2007). 
 
2.3.5 Effects upon adipogenesis 
Niacin stimulates adipogenesis (enhancing PPARγ, FABP4, adiponectin and leptin expression) 
in 3T3-L1 cells, while supresses C/EBPβ and, thereby, cyclooxygenase-2 expression, which is 
responsible for PGF2α (anti-adipogenic factor) decrease in adipocytes (Fujimori and Amano 
2011). 
2.4 Ezetimibe 
Ezetimibe acts by inhibiting intestinal cholesterol absorption (through Niemann-Pick C1-Like 1 
(NPC1L1) transporter) and by decreasing its delivery to liver, leading to upregulation of hepatic 
LDL receptors (Jellinger et al. 2017). Used in monotherapy it can achieve LDL reductions of 
10%-18% and, in combination with statins, LDL reductions of 34%-61% (Jellinger et al. 2017). 
Ezetimibe is also able to reduce Apo-B levels (11%-16%) (Jellinger et al. 2017). Currently, 
ezetimibe displays a supportive role in dyslipidemia treatment, being used mostly in combination 
with other antidyslipidemic (Takase et al. 2012). 
2.4.1 Effects upon adipocyte metabolic functions 
Ezetimibe decreases fat visceral accumulation, without affecting total body weight (Takase et al. 
2012). It also improves hepatic steatosis (Takase et al. 2012). 
 
2.4.2 Effects upon inflammation 
Ezetimibe seems to affect plasma adipokines (Krysiak et al. 2014b). Indeed, by acting in AT, 
ezetimibe has been shown to lower visfatin, while increasing adiponectin plasma levels (Krysiak 
et al. 2014b; Takase et al. 2012). The combination of Ezetimibe-simvastatin treatment for 30 days 
was able to partially revert AT dysfunction and decrease systemic inflammation, independently 
of the lipid-lowering effect (Krysiak et al. 2014a). This combination decreases leptin, visfatin, 
TNFα and increases adiponectin levels, supporting a direct effect on AT production/secretion of 
these adipokines (Krysiak et al. 2014a). 
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2.4.3 Effects upon insulin sensitivity 
Ezetimibe is able to improve insulin resistance, especially in patients with MS (Takase et al. 
2012). Moreover, ezetimibe effects seem to be more potent in insulin-resistant patients (Krysiak 
et al. 2014b). 
The effects of the drugs used on dyslipidemia upon the AT are summarized on table 2.1 and fig. 
2.1 and 2.2. 
 
3 Drugs used in obesity 
 
3.1 Orlistat 
Orlistat inhibits gastric and pancreatic lipases (Heck et al. 2000), thus reducing fat intestinal ab-
sorption. As a result, orlistat decreases body weight (weight loss of 3% (Orlistat prescribing 
information)), improves glucose intolerance and ameliorates lipid parameters (total cholesterol 
and LDL) (Beg et al. 2015; Kim et al. 2013). In addition, orlistat can reverse liver steatosis but 
not adipocyte hypertrophy (Beg et al. 2015).  
 
3.1.1 Effects upon adipocyte metabolic functions 
Orlistat partially inhibits lipolysis in adipocytes by suppressing AMPK activation and decreasing 
AMP/ATP ratio induced by forskolin, isoproterenol and IBMX (agents that increase cAMP lev-
els), without altering PKA activity and cAMP levels (Gauthier et al. 2008). On the other hand, 
orlistat has a lipolytic effect, inducing TG degradation in AT and liver and downregulating leptin 
expression (Kim et al. 2013). 
 
3.1.2 Effects upon inflammation 
Orlistat combined with a hypocaloric diet was able to produce a marked reduction in plasma con-
centrations of leptin, CRP, IL-6, TNFα and resistin, while increasing adiponectin levels 
(Bougoulia et al. 2006; Hsieh et al. 2005). Thus, orlistat seems to have a role in improving obesity-
related AT dysfunction (Bougoulia et al. 2006; Hsieh et al. 2005). 
 
3.2 Anorexiants/ Central nervous system stimulants 
3.2.1 Sibutramine 
Sibutramine is an inhibitor of NA and 5-hydroxytryptamine (5-HT) neuronal reuptake. It has been 
withdrawn of the market due to its nefast cardiovascular side-effects. Sibutramine induces weight 
loss of 5%, decreases waist circumference and improves several metabolic parameters 
(Valsamakis et al. 2004). Sibutramine decreases serum TG and CRP, while increasing serum HDL 
levels and insulin sensitivity (Valsamakis et al. 2004). Globally, it exhibits an anti-inflammatory 
role, lowering both leptin and resistin and increasing adiponectin levels (Valsamakis et al. 2004).  
3.2.2 Diethylpropion 
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Diethylpropion, a sympathomimetic amine similar to amphetamine, is a prodrug metabolized to 
2-ethylamino-1-phenyl-propan-1-one and N, N-diethylnorephedrine metabolites (Yu et al. 2000), 
the latter being responsible for diethylpropion effects. This metabolite acts as substrate for NA 
transporter, with a higher potency (10 times higher than dopamine (DA)) leading to inhibition of 
NA reuptake, while stimulating NA release (Yu et al. 2000). It also acts as a reuptake inhibitor of 
both DA and 5-HT transporters (Yu et al. 2000). The increase in NA concentrations in brain could 
justify both the anorexiant effect and the side-effects common to amphetamine use (Yu et al. 
2000). 
3.2.3 Phentermine and Lorcaserin 
Phentermine is a sympathomimetic amine similar to amphetamine, though with residual additive 
potential. Additionally, it acts as DA receptor agonist and, partially, as NA receptor partial agonist 
or antagonist (Dobrzanski and Doggett 1979) while Lorcaserin (Bays 2009, 2011) is a 5-HT 2c 
receptor agonist. Both drugs decrease food intake while increase satiety, causing weight losses of 
(Bays 2009, 2011; Dobrzanski and Doggett 1979), respectively 5% (Phentermine prescribing 
information  2012) and 8% (Lorcaserin prescribing information). 
3.3 Antidepressants 
3.3.1 Naltrexone and Bupropion 
Naltrexone and Bupropion are respectively, an antagonist of opioid-receptors in pro-opiomelano-
cortin (POMCs) neurons, and a NA and DA reuptake inhibitor. The combined treatment with 
these drugs decreases food intake, body weight (weight loss exceeding 8% of baseline body 
weight (Naltrexone SR-bupropion SR prescribing information. )) and fat mass (without changing 
lean mass) in diet-induced obese rats (Clapper et al. 2013; Smith et al. 2013). Noteworthy, this 
combination decreases VAT mass (Smith et al. 2013).The addition of amylin (a peptide co-re-
leased with insulin by pancreatic β cells) to the combined treatment produces an additive effect, 
showing even better results in the referred parameters (Clapper et al. 2013), due to modulation of 
melanocortin (MC) pathway (increasing the expression of MC4 receptor in hypothalamic neu-
rons) (Clapper et al. 2013).  
 
3.4 Antiepileptics 
3.4.1 Topiramate 
Topiramate is an antiepileptic drug that acts as antagonist of AMPA (α-amino-3-hydroxy-5-me-
thyl-4-isoxazolepropionic acid) receptors and positively modulates gamma-aminobutyric acid 
(GABA) receptors. It is also used as anticonvulsiant, analgesic and humor-stabilizer. Topiramate 
induces a significant weight loss (Abo-Elmatty and Zaitone 2011). Moreover, it decreases glyce-
mia, insulinemia, insulin resistance and TG, while increases adiponectin plasma levels in diet-
induced obesity rats (Abo-Elmatty and Zaitone 2011). Topiramate does not affect arterial pressure 
or anxiety. The mechanisms involved in these effects are not fully understood. Nonetheless, inhi-
bition of food ingestion, downregulation of leptin expression and upregulation of UCP-2 and 3 
expressions in WAT and BAT seem to be mechanisms also involved (York et al. 2000). 
3.5 Liraglutide 
Liraglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) firstly approved as anti-
diabetic drug, though more recently in higher doses as anti-obesity drug, providing 9% weight 
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loss (Nordisk 2016). It is indicated for obese or overweight adults with at least one obesity-related 
comorbidity (Nordisk 2016). GLP-1 is an endogenous incretin, secreted by L cells in distal intes-
tine (Kieffer and Habener 1999; Holst et al. 1987). Liraglutide, by increasing GLP-1 levels, re-
duces food ingestion, appetite (Inoue et al. 2011; Shao et al. 2015; Jensterle et al. 2015; Hoang et 
al. 2015; Nonogaki et al. 2014; Heppner et al. 2015) and change food preferences, namely im-
proving eating behaviours and decreasing emotional eating, which increases weight loss (Inoue 
et al. 2011; Jensterle et al. 2015). Liraglutide can slow gastric emptying (Hoang et al. 2015), a 
mechanism contributing to reduce food intake. 
GLP-1 was described as having anti-adipogenic, anti-lipogenic and pro-lipolytic effects in human 
mature adipocytes (El Bekay et al. 2016). Furthermore, GLP-1 was discovered to activate GLP-
1R in central nervous system (CNS) leading to an increase in BAT activity and energy expendi-
ture (Heppner et al. 2015). 
3.5.1 Effects upon adipocyte metabolic functions 
Even in short-term treatment, liraglutide induces a sustained decrease of body weight and BMI 
(Li et al. 2014; Tang et al. 2015; Suzuki et al. 2013; Yang et al. 2012; Inoue et al. 2011; Jendle et 
al. 2009; Yan et al. 2011; Morano et al. 2015; Shao et al. 2015; Jensterle et al. 2015; Hoang et al. 
2015; Nonogaki et al. 2014; Beiroa et al. 2014) mainly due to a reduction in total fat mass and in 
fat thickness of different depots (although not equally) (Li et al. 2014; Tang et al. 2015; Suzuki 
et al. 2013; Yang et al. 2012; Inoue et al. 2011; Jendle et al. 2009; Morano et al. 2015; Beiroa et 
al. 2014). Noteworthy, liraglutide is also capable of changing regional distribution of fat depots 
(Li et al. 2014; Tang et al. 2015; Suzuki et al. 2013; Yang et al. 2012; Inoue et al. 2011; Jendle et 
al. 2009; Morano et al. 2015; Shao et al. 2015; Hoang et al. 2015) and acts mainly by decreasing 
VAT (Li et al. 2014; Tang et al. 2015; Suzuki et al. 2013; Yang et al. 2012; Inoue et al. 2011; 
Jendle et al. 2009; Morano et al. 2015; Shao et al. 2015; Jensterle et al. 2015; Hoang et al. 2015). 
In contrast, other studies describe a preferential liraglutide effect in SCAT (Suzuki et al. 2013). 
Even in models of insulin resistance, adiponectin and apo-E knockout and polycystic ovarian 
syndrome models (not responding to metformin and typical weight-loss strategies), liraglutide 
seems able to decrease body weight (Yang et al. 2012; Jensterle et al. 2015; Hoang et al. 2015). 
 
The liraglutide-induced weight loss seems to increase NPs concentrations (Li et al. 2014), which 
induces lipid oxidation (Beiroa et al. 2014; Li et al. 2014). The ANP and BNP increase is higher 
in patients that lose more than 5% of their body weight and seems to be significantly correlated 
with liraglutide effects on body composition (Li et al. 2014). Besides, reducing lipid storage in 
WAT, decreases lipogenesis (Shao et al. 2015). These effects seem to be driven by downregula-
tion of Akt and PI3K pathways and upregulation of AMPK and ACC genes (Shao et al. 2015). 
Furthermore, liraglutide was shown to increase energy expenditure, by inducing the browning of 
WAT and BAT, increasing thermogenesis (Beiroa et al. 2014; Li et al. 2014; Heppner et al. 2015). 
This browning effect was also shown to be driven by an increase in NP which stimulates MAPK 
pathway (Li et al. 2014). Nevertheless, the magnitude of increase in BAT activity is modest and 
seems not to justify the extent of liraglutide effect in weight loss (Heppner et al. 2015). Lirag-
lutide, through stimulation of CNS GLP-1R on ventromedial hypothalamic nuclei and modulation 
of AMPK pathway, was shown to decrease body weight (Beiroa et al. 2014), independently of 5-
HT2CR and MC4R pathways (Nonogaki et al. 2014). 
 
3.5.2 Effects upon inflammation 
Liraglutide has been described to regulate adipokines secretion in opposite directions. In T2DM 
patients, it decreases total adiponectin levels while increases pentraxin 3, a marker of inflamma-
tory cardiovascular disease, and proinsulin levels (Suzuki et al. 2013). This latter demonstrates a 
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beneficial effect upon pancreas β-cell function (Suzuki et al. 2013). On the other hand, in obese 
patients, liraglutide increases adiponectin expression and inhibits glucose uptake in adipocyte 
stem cells (Cantini et al. 2015). Liraglutide also decreases TNFα and adiponectin expression in 
human adipocytes (El Bekay et al. 2016).  
 
3.5.3 Effects upon atherogenesis 
Besides improving lipid profile, liraglutide decreases CRP levels and soluble ICAM-1 (Inoue et 
al. 2011).  Thus, it seems to have pleiotropic effects and an anti-atherosclerotic role (Inoue et al. 
2011).  
 
 
 
3.5.4 Effects upon obesity-related cardiovascular comorbidities 
GLP-1R are more expressed in adipocytes from VAT and obese T2DM patients, comparing to 
those of lean patients (El Bekay et al. 2016). 
Liraglutide can improve insulin sensitivity, even in insulin resistant models. Omentin (an adi-
pokine mainly produced by VAT), through Akt/PKb signaling pathway stimulation (Yang et al. 
2006; Bai et al. 2007), increases glucose transport induced by insulin, improving insulin sensitiv-
ity and glucose metabolism (Yan et al. 2011). The omentin plasma levels are decreased in T2DM 
(suggesting a deregulation of omentin biosynthesis or a response to hyperglycemia and hyperin-
sulinemia) and liraglutide can increase omentin plasma levels (Yan et al. 2011). Liraglutide in-
creases ZAG (Zinc alpha2 glycoprotein), a protein involved in multiple effects such as body 
weight control and lipolysis, and adiponectin plasma levels. ZAG levels are decreased in obesity 
and T2DM, suggesting that it could be involved in insulin resistance pathogenesis (Yang et al. 
2013).  
Moreover, liraglutide improves insulin secretion (Li et al. 2014; Yan et al. 2011; Hoang et al. 
2015; Yang et al. 2012), increasing glucose uptake in peripherical tissues (Nonogaki et al. 2014). 
Liraglutide increases PPARγ activity, stimulating liver production of fibroblast growth factor-21 
(FGF21) expression, which leads to an increase in FGF21 plasma levels (Nonogaki et al. 2014). 
In obese or T2DM patients, FGF21 mRNA expression and plasma levels are elevated (a compen-
satory mechanism to decrease insulin resistance). It reflects a decrease in FGF receptor (FGFR) 
supporting an FGF21 resistance in these conditions (Yang et al. 2012). Furthermore, in AT, lirag-
lutide also upregulates the expression of FGFR3 and B-Klotho (necessary to the binding of FGF21 
to its receptor) while, in liver, it upregulates FGFR1-3, B-klotho and phospho-FGFR1 expression 
(Yang et al. 2012). In this way, since FGF21 is an important regulator of insulin effects upon 
glucose and lipid metabolism, liraglutide could contribute to improve insulin action (Nonogaki et 
al. 2014; Yang et al. 2012).  
Liraglutide has been described as a fat liver modulator. In contrast with some studies, showing no 
effect upon fat liver parameters (Tang et al. 2015), liraglutide has been shown to decrease hepatic 
fat, even in obese and/or T2DM patients (Suzuki et al. 2013; Jendle et al. 2009; Cuthbertson et al. 
2012). The decrease in intrahepatic lipids does not correlate with changes in weight, abdominal 
fat, VAT, SCAT or adiponectin levels, but rather with a decrease in HbA1c (Cuthbertson et al. 
2012). Authors proposed that this effect is due to an increase in glucose tolerance, thus reducing 
hyperinsulinemia (Cuthbertson et al. 2012), which is followed by a decrease in lipogenesis rate 
and an increase in FA oxidation. Treatment with liraglutide improves systolic blood pressure and 
lipid profile, decreasing plasma total cholesterol and TG, while increasing HDL levels (Jendle et 
al. 2009; Hoang et al. 2015; Yang et al. 2012; Inoue et al. 2011; Li et al. 2014). 
 
3.5.5 Effects upon adipogenesis 
GLP-1 and GLP-1RA are able to regulate preadipocyte differentiation, even they act differently 
according to adipocyte origin or differentiation stage.  
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Liraglutide stimulates the early phase of adipogenesis in 3T3-L1 cells by inducing the expression 
of PPARγ, C/EBPβ and δ, and GLP-1R, a target gene of PPARγ (Challa et al. 2012). This effect 
is due to modulation of both survival and proliferation pathways, mainly, ERK1/2, PKCβ and Akt 
(Challa et al. 2012). 
In contrast, liraglutide inhibits both proliferation and differentiation of ASCs obtained from obese 
patients, by binding directly to GLP-1R (Cantini et al. 2015).  GLP-1RA decreases the expression 
of adipogenesis and lipogenesis related genes, while increasing expression of lipolytic ones (El 
Bekay et al. 2016). In contrast to 3T3-L1 cells, in human adipocytes, GLP-1 anti-adipogenic effect 
is not mediated by the same pathways, Akt and ERK1/2, instead it is driven through inactivation 
of the AC/cAMP pathway (El Bekay et al. 2016).  
The effects of drugs used in obesity upon AT are summarized on table 3.1 and figures 2.1 and 
2.2. 
4 Conclusion 
Adipose tissue is a complex organ with marked effects on whole-body physiology. AT dysregu-
lation, rather than the amount of fat mass, seem to be a key factor in the pathophysiology of 
obesity and related morbidities. Despite the increase in the number of drugs available to treat 
these conditions, dyslipidemia and obesity prevalence still remains rising. AT dysregulation is a 
main feature present in both dyslipidemia and obesity. In this review, the effects of drugs used to 
treat dyslipidemia and obesity were analysed focusing on AT. The main adipocyte metabolic ef-
fects, the effects on inflammation, atherogenesis, insulin sensitivity, and adipogenesis were re-
vised to explore how these drugs can modulate these complex pathways. Furthermore, we denote 
differences between drugs of the same class that could be of major importance for clinical prac-
tice. At the same time, despite a favourable clinical effect, some drugs can have adverse effects 
on adipocyte function. Gathering all this evidence, is relevant to question whether answers to 
these difficulties will be found through new advances in pharmacology or in further adjustments 
and combinations between drugs already in use. A thoroughly understanding of the role of AT in 
these conditions, as the impact these drugs have on its functions can become the next step in order 
to tackle CVD, becoming part of the challenges that physicians face nowadays. 
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Figures legends 
 
Fig. 1.1 Schematic illustration of the main intracellular pathways underlying: A) differentiation of preadipocytes 
into mature adipocytes. This process is on dependence of PKA pathway, which activates transcriptional factors such 
as C/EBPβ, C/EBPδ, C/EBPα and PPARγ, that ultimately lead to increase of adipogenesis genes (such as Leptin; 
Adiponectin, FABP4, perilipin, GLUT4, SCD1) expression and B) immune and endocrine functions of WAT. Adi-
pocyte exerts autocrine and paracrine actions, through secreting adipokines (mainly Leptin and Adiponectin) and also 
endocrine in distant organs through circulation. See text for more details. Symbols: → stimulates; ⊣ inhibits; Abbrevi-
ations: adenylyl cyclase (AC); cyclic adenosine monophosphate (cAMP); cAMP-dependent protein kinase A (PKA); 
CCATT enhancer-binding proteins (C/EBP); peroxisome proliferator-activated receptors (PPARs); sterol regulatory 
element-binding protein-1 (SREBP1); retinoid X receptor-α (RXRα); sterol response elements (SRE); scavenger-re-
ceptor 1 (SRB1); natural killer cells (NK cells);  Cluster of differentiation 40 (CD40); CD40 ligand (CD40L); 11β-
Hydroxysteroid dehydrogenase type 1 (11β-HSD1); Tumour-necrosis factor α (TNFα); interleukin (IL); CC-chemokine 
ligand 2 (CCL2 or MCP-1); plasminogen-activator inhibitor type 1 (PAI-1); adiponectin receptor (AdipoR); IL-1 re-
ceptor antagonist (IL-1RA); interferon- γ (IFN-γ); Toll-like receptors (TLR); nuclear factor kappa B (NF-kB); scaven-
ger-receptor 1 (SR-B1); vascular cell adhesion molecule-1 (VCAM-1), endothelial-leukocyte adhesion molecule-1 (E-
selectin), and intracellular adhesion molecule-1 (ICAM-1); leptin receptor (OBRb); extracellular-signal-regulated ki-
nase (ERK); p38 mitogen-activated protein kinases (MAPK); inducible nitric-oxide synthase (iNOS); reactive oxygen 
species (ROS); TNF receptor (TNFR); NF-κB kinase-β (IKKβ); JUN N-terminal kinase (JNK); endoplasmic-reticulum 
(ER); insulin receptor (IR) substrate (IRS); uncoupling protein (UCP); adenylyl cyclase-associated protein 1 (CAP1); 
endothelin-1 (ET-1). 
Fig. 1.2 Schematic illustration of the main intracellular pathways underlying WAT metabolic functions: β-oxi-
dation (*through upregulation of ACS, CD36, MCD, CPT1 genes expression and, when upon certain stimulus, as 
PPAR-α agonist or adrenergic receptor stimulation, through upregulation of AMPK pathway); lipolysis (through the 
sequential action of ATGL; HSL; MGL); lipogenesis (*through upregulation of GLUT4; ACC genes). See text for 
more details. Symbols: → stimulates; ⊣ inhibits; Abbreviations: triglycerides (TG); fatty acid (FA); cholesterol (Ch); 
lipoprotein lipase (LPL); very low-density lipoproteins (VLDL); diacylglycerol acyltransferase (DGAT); enzyme ace-
tyl-coenzyme A carboxylase (ACC); sterol regulatory element-binding protein 1 (SREBP1); carbohydrate response 
element-binding protein (ChREBP); glucose transporter type 4 (GLUT4); phosphoinositide 3-kinase-dependent (PI3-
K); phosphodiesterase 3B (PDE3B); adenylyl cyclase (AC); cyclic adenosine monophosphate (cAMP); cAMP-depend-
ent protein kinase A (PKA); Protein Kinase B (PKB/Akt); guanylyl cyclase activity (GC); cyclic guanosine monophos-
phate (cGMP); cGMP-dependent protein kinase (PKG); adipocyte triglyceride lipase (ATGL); hormone-sensitive li-
pase (HSL); monoacylglycerol lipase (MGL); peroxisome proliferator-activated receptors (PPARs); peroxisome 
proliferator activated receptor γ coactivator 1 (PGC-1α); acyl-CoA synthetase (ACS); fatty acid translocase 
(CD36/FAT); carnitine palmitoyl transferase 1 (CPT1); adrenoceptors (AR); atrial or brain natriuretic peptide 
(ANP/BNP); natriuretic receptor A (NPR-A); insulin receptor (IR) substrate (IRS); adenosine monophosphate-acti-
vated protein kinase (AMPK); sirtuin 1 (SIRT1); brown adipose tissue (BAT); high-density lipoproteins (HDLs); , 
LXRα (liver X receptor alpha); ATP binding cassette A1 (ABCA1) transporter; scavenger-receptor 1 (SRB1). 
Fig. 2.1 Schematic illustration of the effects of drugs used in dyslipidemia and obesity upon WAT metabolic 
functions and their underlying pathways. Statins induce adipocyte FA uptake, reinforcing this effect by increasing 
LPL expression, while decreasing cholesterol release. *only in obese models, statins stimulate lipogenesis de novo; 
globally, fibrates inhibit lipogenesis and stimulate FA oxidation (*through upregulation of ACS, CD36, MCD, CPT1 
genes expression) and thermogenesis (*through upregulation of PRDM16, PPAR-γ and UCP-1 genes expression); Ni-
acin inhibits lipolysis and increases lipogenesis genes expression (*GLUT4; ACC); Orlistat enhances TG degradation. 
*AMPK pathway stimulation occurs upon certain stimulus, such as PPAR-α agonists or adrenergic receptor stimula-
tion. See text for more details. Symbols: → stimulates; ⊣ inhibits; Anti-obesity drugs are inserted in green boxes while 
anti-dyslipidemic drugs are inserted in purple boxes. Abbreviations: triglycerides (TG); fatty acid (FA); cholesterol 
(Ch); lipoprotein lipase (LPL); very low-density lipoproteins (VLDL); diacylglycerol acyltransferase (DGAT); enzyme 
acetyl-coenzyme A carboxylase (ACC); sterol regulatory element-binding protein 1 (SREBP1); carbohydrate response 
element-binding protein (ChREBP); glucose transporter type 4 (GLUT4); phosphoinositide 3-kinase-dependent (PI3-
K); phosphodiesterase 3B (PDE3B); adenylyl cyclase (AC); cyclic adenosine monophosphate (cAMP); cAMP-depend-
ent protein kinase A (PKA); Protein Kinase B (PKB/Akt); guanylyl cyclase activity (GC); cyclic guanosine monophos-
phate (cGMP); cGMP-dependent protein kinase (PKG); adipocyte triglyceride lipase (ATGL); hormone-sensitive li-
pase (HSL); monoacylglycerol lipase (MGL); peroxisome proliferator-activated receptors (PPARs); peroxisome 
proliferator activated receptor γ coactivator 1 (PGC-1α); acyl-CoA synthetase (ACS); fatty acid translocase 
(CD36/FAT); carnitine palmitoyl transferase 1 (CPT1); adrenoceptors (AR); atrial or brain natriuretic peptide 
(ANP/BNP); natriuretic receptor A (NPR-A); insulin receptor (IR) substrate (IRS); adenosine monophosphate-acti-
vated protein kinase (AMPK); sirtuin 1 (SIRT1); brown adipose tissue (BAT); high-density lipoproteins (HDLs); , 
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LXRα (liver X receptor alpha); ATP binding cassette A1 (ABCA1) transporter; scavenger-receptor 1 (SRB1); n-3 
polyunsaturated fatty acids (PUFAs). 
Fig. 2.2 Schematic illustration of the effects of drugs used in dyslipidemia and obesity upon: A) differentiation 
of preadipocytes into mature adipocytes Statins and liraglutide inhibit adipogenesis while niacin and fibrates stimu-
late, by inducing upregulation of adipogenesis genes (*Leptin; Adiponectin, FABP4, perilipin, GLUT4, SCD1) expres-
sion and B) immune and endocrine functions of WAT Most of drugs exhibit an anti-inflammatory role through 
modulation of adipokine expression. Moreover, through modulation of leucocyte chemotaxis, affect NK cells activity 
and macrophage phagocytosis. See text for more details. Symbols: → stimulates; ⊣ inhibits; Anti-obesity drugs are 
inserted in green boxes while anti-dyslipidemic drugs are inserted in purple boxes. Abbreviations: adenylyl cyclase 
(AC); cyclic adenosine monophosphate (cAMP); cAMP-dependent protein kinase A (PKA); CCATT enhancer-binding 
proteins (C/EBP); peroxisome proliferator-activated receptors (PPARs); sterol regulatory element-binding protein-1 
(SREBP1); retinoid X receptor-α (RXRα); sterol response elements (SRE); scavenger-receptor 1 (SRB1); natural killer 
cells (NK cells);  Cluster of differentiation 40 (CD40); CD40 ligand (CD40L); 11β-Hydroxysteroid dehydrogenase 
type 1 (11β-HSD1); Tumour-necrosis factor α (TNFα); interleukin (IL); CC-chemokine ligand 2 (CCL2 or MCP-1); 
plasminogen-activator inhibitor type 1 (PAI-1); adiponectin receptor (AdipoR); IL-1 receptor antagonist (IL-1RA); 
interferon- γ (IFN-γ); Toll-like receptors (TLR); nuclear factor kappa B (NF-kB); scavenger-receptor 1 (SR-B1); vas-
cular cell adhesion molecule-1 (VCAM-1), endothelial-leukocyte adhesion molecule-1 (E-selectin), and intracellular 
adhesion molecule-1 (ICAM-1); leptin receptor (OBRb); extracellular-signal-regulated kinase (ERK); p38 mitogen-
activated protein kinases (MAPK); inducible nitric-oxide synthase (iNOS); reactive oxygen species (ROS); TNF re-
ceptor (TNFR); NF-κB kinase-β (IKKβ); JUN N-terminal kinase (JNK); endoplasmic-reticulum (ER); insulin receptor 
(IR) substrate (IRS); uncoupling protein (UCP); adenylyl cyclase-associated protein 1 (CAP1); endothelin-1 (ET-1).  
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Tables 
Table 2.1 Drugs used in Dyslipidemia: classical effects, effects upon adipose tissue and weight 
Drugs 
used in 
Dyslipi
demia 
Classical 
mechanis
m of 
action 
Adipose tissue effects 
Weight 
AT mass/ 
AT 
depots 
Glucose 
metabolism/ 
Insulin 
sensitivity 
Lipid 
metabolism 
Adipokines expression 
Anti-
atherogenic 
Adipoge
nesis 
Brownin
g effect 
Anti-
inflammat
ory 
↑ ↓ 
Statins ⊝ HMG 
-CoA 
reductas
e enzyme 
↓ EAT 
(Alexopoulo
s et al. 2013) 
⊝ caveolae 
dysfunction 
(Breen et al. 2012);  
⊝ GLUT4 
expression and 
translocation 
(Ganesan and Ito 
2013); NLRP3 
inflammasome 
activation 
(Henriksbo et al. 
2014); 
⊕ ↑ SIRT1 and 
PGC-1α leading 
to PPARy and 
GLUT4 (de las 
Heras et al. 2013; 
Valero-Munoz et al. 
2014; Poletto et al. 
2015); 
modulation of 
adipokines 
expression 
(Takagi et al. 2008; 
Poletto et al. 2015) 
⊕ lipolysis 
(Ishihara et al. 
2010) 
↓ lipid 
accumulatio
n (⊕ LPL) 
(Bey et al. 2002; 
Saiki et al. 2006) 
⊕ 
lipogenesis 
and ↑ lipid 
accumulatio
n (Aguirre et al. 
2013) 
Adiponectin 
(Labuzek et al. 2011; 
Lobo et al. 2012; Yin et 
al. 2007; Ishihara et al. 
2010; Li et al. 2016; 
Krysiak et al. 2014c) 
Leptin (Krysiak et al. 
2014c; Labuzek et al. 
2011; Maeda and 
Horiuchi 2009; Zhao 
and Wu 2005; Krysiak et 
al. 2014d), Resistin 
(Ichida et al. 2006; 
Labuzek et al. 2011; Li 
et al. 2016), IL-6 
(Labuzek et al. 2011; 
Zhao and Zhang 2003; 
Dobashi et al. 2008; Yin 
et al. 2007; Wang et al. 
2014; Abe et al. 2008), 
PAI-1 (Laumen et al. 
2008; Lobo et al. 2012; 
Sakamoto et al. 2011), 
MCP-1  (Lobo et al. 
2012; Wu et al. 2013; 
Wang et al. 2014; 
Takagi et al. 2008; Abe 
et al. 2008); Visfatin 
(Krysiak et al. 2014d) 
and TNF-α (Krysiak 
et al. 2014c; Labuzek et 
al. 2011; Wu et al. 2013; 
Wang et al. 2014; 
Krysiak et al. 2014d; 
Takagi et al. 2008) 
⊕ PPARγ 
and SR-BI 
expression 
(adipocyte 
uptake of ox-
LDL) (Zhao et 
al. 2006; Zhao and 
Zhang 2004); 
Vide 
adipokines 
expression 
modulation. 
⊝ 
(Pengde et 
al. 2008; 
Song et al. 
2003; 
Zhang et al. 
2013; 
Elfakhani 
et al. 2014) 
⊕ in 
vivo 
(Khan et al. 
2009; 
Phillips et 
al. 2001) 
 ⊝ ER 
stress (Wu et 
al. 2013); 
⊕ iNOS 
expression 
(Araki et al. 
2007; Dobashi 
et al. 2008); 
 
̶   (de las 
Heras et al. 
2013; Valero-
Munoz et al. 
2014) 
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Drugs 
used in 
Dyslipi
demia 
Classical 
mechanis
m of 
action 
Adipose tissue effects 
Weight 
AT mass/ 
AT 
depots 
Glucose 
metabolism/ 
Insulin 
sensitivity 
Lipid 
metabolism 
Adipokines expression 
Anti-
atherogenic 
Adipoge
nesis 
Brownin
g effect 
Anti-
inflammat
ory 
↑ ↓ 
Fibrate
s 
PPARα 
agonists 
      ⊕ (Goto 
et al. 2011; 
Brandes et 
al. 1986) 
  ↓ (Chen et al. 
2014; 
Vazquez et al. 
2001; Jeong 
and Yoon 
2009; 
Gonzalez et al. 
2009; Ferreira 
et al. 2014; 
Rachid et al. 
2015b, a) 
Bezafib
rate 
Non-
selective 
  ⊕ FA 
oxidation 
(Cabrero et al. 
2001; Vazquez et 
al. 2001; Goto et 
al. 2011) 
⊝ 
lipogenesis 
(Cabrero et al. 
2001) 
Adiponectin 
(Nakano et al. 2007; 
Hiuge et al. 2007) 
TNFα (Nakano et al. 
2007; Hiuge et al. 2007) 
  ⊕ UCP-
1,2,3 
expressio
n (Cabrero 
et al. 2001; 
Vazquez et 
al. 2001) 
  
Gemfib
rozil 
Selective   ⊕ 
lipogenesis 
(Baldo et al. 
1994) 
       
Fenofib
rate 
selective ↓ VAT 
(Jeong and 
Yoon 2009) 
⊕ (Jeong and Yoon 
2009; Rachid et al. 
2015a; Ferreira et al. 
2014) 
⊕ FA 
oxidation 
(Gonzalez et al. 
2009; Ferreira et 
al. 2014) 
⊝ 
lipogenesis 
(Ferreira et al. 
2006) 
Adiponectin 
(Labuzek et al. 2011; 
Oki et al. 2007); 
Vaspin (Chen et al. 
2014) 
MCP1 (Toyoda et al. 
2008); TNFα 
(Labuzek et al. 2011; 
Toyoda et al. 2008; 
Zhao and Wu 2004; 
Jeong and Yoon 2009); 
Leptin (Jeong and 
Yoon 2009; Rachid et al. 
2015a) 
⊕ oxLDL 
uptake (Zhao et 
al. 2004) 
⊕ CD36 
expression 
(Zhao et al. 2004) 
 ⊕ (Rachid 
et al. 2015b, 
a) 
⊝ CD40 
expression 
(AMPK 
pathway) 
(Wang et al. 
2013) 
⊝ AOX1 
expression 
(Weigert et al. 
2008) 
↓ (Ferreira et 
al. 2014; 
Jeong and 
Yoon 2009; 
Gonzalez et al. 
2009; Rachid 
et al. 2015b, a) 
Ezetimi
be 
⊝ 
NPC1L1 
↓ VAT 
(Takase et 
al. 2012) 
⊕ (Takase et al. 
2012) 
 Adiponectin 
(Takase et al. 2012) 
Visfatin (Krysiak et 
al. 2014b) 
    ̶  (Takase et 
al. 2012) 
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Drugs 
used in 
Dyslipi
demia 
Classical 
mechanis
m of 
action 
Adipose tissue effects 
Weight 
AT mass/ 
AT 
depots 
Glucose 
metabolism/ 
Insulin 
sensitivity 
Lipid 
metabolism 
Adipokines expression 
Anti-
atherogenic 
Adipoge
nesis 
Brownin
g effect 
Anti-
inflammat
ory 
↑ ↓ 
transport
er 
Niacin ⊝ HDL-
apo A-I 
holoparti
cle 
receptor 
in 
hepatocy
tes 
 ⊝ (Westphal et al. 
2007; Heemskerk et 
al. 2014b) 
⊕ lipolysis 
(Carlson 1963; 
Plaisance et al. 
2009; Zhang et 
al. 2005)  
⊝ 
lipogenesis 
Adiponectin 
(Plaisance et al. 
2009);Leptin 
(chronic 
treatment) 
(Westphal et al. 2007) 
MCP1, RANTES, 
Fractalkine (Digby 
et al. 2010) 
↑ n-3 PUFAs 
and its 
metabolites 
(Heemskerk et al. 
2014a); 
 ⊕ HDL-
induced 
cholesterol 
efflux from 
adipocytes; ↑ 
HDL levels 
(Wu and Zhao 
2009; Zhao et al. 
2008) 
⊕ 
(Fujimori 
and Amano 
2011) 
 Vide 
adipokines 
effects 
 
Symbols: ⊕ stimulates; ⊝ inhibits; - without effect; Abbreviations: adipose tissue (AT); triglycerides (TG); 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA); glucose transporter type 4 (GLUT4); NOD-like receptor family, pyrin domain 
containing 3 (NLRP3); sirtuin 1 (SIRT1); peroxisome proliferator-activated receptors (PPARs); peroxisome proliferator activated receptor γ coactivator 1 (PGC-1α); lipoprotein lipase (LPL); tumour-necrosis factor α (TNFα); interleukin (IL); CC-
chemokine ligand 2 (CCL2 or MCP-1); plasminogen-activator inhibitor type 1 (PAI-1); scavenger-receptor 1 (SRB1); oxidized LDL (oxLDL); fatty acid translocase (CD36/FAT); endoplasmic-reticulum (ER); inducible nitric-oxide synthase (iNOS); 
uncoupling protein (UCP); Niemann-Pick C1-Like 1 (NPC1L1); visceral AT (VAT); fatty acid (FA); adenosine monophosphate-activated protein kinase (AMPK); Aldehyde oxidase 1 (AOX1); Cluster of differentiation 40 (CD40); soluble intracellular 
adhesion molecule-1 (sICAM-1); high-density lipoproteins (HDLs); n-3 polyunsaturated fatty acids (PUFAs). 
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Table 3.1 Drugs used in Obesity: classical effects, effects upon adipose tissue and weight 
 
Drugs used in 
Obesity 
Classical 
mechanism of 
action 
Adipose tissue effects 
Appetite 
regulation 
AT mass/ 
AT depots 
Glucose 
metabolism/ 
Insulin 
sensitivity 
Lipid 
metabolism 
Adipocytokines 
expression Anti-
atherogenic 
Adipogenesis 
Browning 
effect 
Anti-
inflammatory 
↑ ↓ 
Orlistat Reversible 
inhibitor of 
gastric and 
pancreatic 
lipase 
 ⊕ (Beg et al. 
2015; Kim et 
al. 2013) 
⊕ lipolysis 
(Kim et al. 
2013) 
 Leptin 
(Kim et al. 
2013) 
     
Sibutramine sympathomimet
ic amine; 
inhibition of 
NA and 5-HT 
reuptake 
  ↓ TG 
(Valsamakis et 
al. 2004) 
↑ HDL 
(Valsamakis et 
al. 2004) 
Adiponec
tin 
(Valsamakis 
et al. 2004) 
Leptin 
and 
Resistin 
(Valsamakis 
et al. 2004) 
↓ CRP 
(Valsamakis et 
al. 2004) 
    
Diethylpropio
n 
sympathomimet
ic amine; 
inhibition of 
NA, 5-HT; DA 
reuptake 
         ⊝ (Yu et al. 
2000) 
Phentermine sympathomimet
ic amine; 
noradrenergic 
modulation; 
         ⊝, 
promotes 
saciety 
(Dobrzanski 
and Doggett 
1979) 
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Drugs used in 
Obesity 
Classical 
mechanism of 
action 
Adipose tissue effects 
Appetite 
regulation 
AT mass/ 
AT depots 
Glucose 
metabolism/ 
Insulin 
sensitivity 
Lipid 
metabolism 
Adipocytokines 
expression Anti-
atherogenic 
Adipogenesis 
Browning 
effect 
Anti-
inflammatory 
↑ ↓ 
DA receptor 
agonist 
Lorcaserin 5-HT2c 
receptor 
agonist 
         ⊝, 
promotes 
saciety (Bays 
2009, 2011) 
Naltrexone 
and 
Bupropion 
Antagonist of 
opioid-
receptors in 
POMCs 
neurons  and 
inhibitor of 
reuptake of NA 
and DA 
↓ , mainly 
VAT (Smith 
et al. 2013) 
         
Topiramate Antagonist of 
AMPA 
receptors and 
stimulation of 
GABA 
receptors 
 ⊕ (Abo-
Elmatty and 
Zaitone 2011) 
 Adiponec
tin (Abo-
Elmatty and 
Zaitone 
2011) 
Leptin 
(York et al. 
2000) 
  ⊕ UCP 
2/3 
expression 
(York et al. 
2000) 
 ⊝ (York et al. 
2000) 
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Drugs used in 
Obesity 
Classical 
mechanism of 
action 
Adipose tissue effects 
Appetite 
regulation 
AT mass/ 
AT depots 
Glucose 
metabolism/ 
Insulin 
sensitivity 
Lipid 
metabolism 
Adipocytokines 
expression Anti-
atherogenic 
Adipogenesis 
Browning 
effect 
Anti-
inflammatory 
↑ ↓ 
Liraglutide 
 
GLP-1R 
agonist 
↓ (Li et al. 2014; 
Tang et al. 2015; 
Suzuki et al. 
2013; Yang et al. 
2012; Inoue et 
al. 2011; Jendle 
et al. 2009; 
Morano et al. 
2015; Beiroa et 
al. 2014), 
mainly VAT 
(Li et al. 2014; 
Tang et al. 2015; 
Suzuki et al. 
2013; Yang et al. 
2012; Inoue et 
al. 2011; Jendle 
et al. 2009; 
Morano et al. 
2015; Shao et al. 
2015; Jensterle 
et al. 2015; 
Hoang et al. 
2015) 
⊕ (Li et al. 
2014; Yan et al. 
2011; Hoang et 
al. 2015; Yang 
et al. 2012) 
⊕ FA 
oxidation 
(Beiroa et al. 
2014; Li et al. 
2014); ⊝ 
lipogenesis 
(Shao et al. 
2015); 
Adiponec
tin (in 
dysfuncti
onal 
adipocyte
) (Cantini et 
al. 2015; 
Yang et al. 
2013); 
Omentin 
(Yan et al. 
2011) 
TNFα (El 
Bekay et al. 
2016) 
↓ CRP and 
sICAM-1 
levels (Inoue 
et al. 2011) 
⊕ (Challa et al. 
2012) 
⊕ (Beiroa et 
al. 2014; Li et 
al. 2014; 
Heppner et al. 
2015) 
Vide 
adipokines 
regulation 
⊝ 
promotes 
saciety and 
improves 
eating 
behaviour 
(Inoue et al. 
2011; Shao et 
al. 2015; 
Jensterle et al. 
2015; Hoang et 
al. 2015; 
Nonogaki et al. 
2014; Heppner 
et al. 2015) 
 
Symbols: ⊕ stimulates; ⊝ inhibits; Abbreviations: adipose tissue (AT); triglycerides (TG); high-density lipoproteins (HDLs); C-reactive protein (CRP); noradrenaline (NA) and 5-hydroxytryptamine (5-HT); dopamine (DA); pro-opiomelanocortin 
(POMCs) neurons; visceral AT (VAT); α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors; gamma-aminobutyric acid (GABA) receptors; fatty acid (FA); tumour-necrosis factor α (TNFα); glucagon-like peptide 1 receptor 
(GLP-1R); soluble intracellular adhesion molecule-1 (sICAM-1). 
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1  Introduction 
Publishing a book is a joint effort between you and Springer. We feel it is important that our authors 
concentrate on the content of the chapter or a book. When writing a book for Springer, please do not be 
concerned with the final layout. That is Springer’s role. To ensure that we always keep pace with all cur-
rent online and print requirements, Springer structures the content in XML as the basis for presentation 
in print or in digital formats for such devices as Amazon Kindle™, Apple iPad™/iPhone™, and Google An-
droid™. We utilize standard layouts with style specifications suitable for multiple display formats. 
• What advantages do these provide for you in manuscript preparation? It means you can focus on the 
content and Springer will professionally typeset the book and, with XML structuring, will ensure that 
your content will be available to readers in many formats for many years to come. To ensure this 
works, please follow the instructions for manuscript formatting, preparation, and delivery under 
Manuscript Preparation. For Lecture Notes in Computer Series (LNCS) preparation guidelines click 
here. 
Tip 
A key part of the publication process (and in response to the changing requirements of the book in-
dustry) is the standard corporate book covers that Springer introduced for each subject area which 
it publishes. These covers provide a strong, corporate brand identity for Springer books, making 
them instantly recognizable amongst the scientific community. In addition the covers also assist the 
speed of publication, as having standardized versions greatly reduces the time traditionally spent on 
creating individual covers for each title. 
2  Manuscript Preparation Tools for Word and LaTeX 
• Springer provides manuscript preparation tools for Word and LaTeX users that help structure the 
manuscript, e.g., define the heading hierarchy. Predefined style formats are available for all the 
necessary structures that are supposed to be part of the manuscript, and these formats can be 
quickly accessed via hotkeys or special toolbars.  
Note: These tools are not intended for the preparation of the final page layout. The final layout will 
be created by Springer according to our layout specifications. 
►Manuscript preparation tool for Word  
►LaTeX2e macro packages for monographs and for contributed books 
• The usage of these tools is not mandatory. Alternatively, you may either use a blank Word docu-
ment or the standard LaTeX book class (for monographs) or article class (for individual contribu-
tions) and apply the default settings and styles (e.g., for heading styles, lists, footnotes, etc.).  
Tip 
If you cannot use our Word tool: 
– Open a blank Word document. 
– Use the default styles in Word to identify the heading levels.  
– Use the standard Word functions for displayed lists, type styles such as bold or italics, the index-
ing function, and the footnote function. 
– Use a single main font for the entire text. We recommend Times New Roman. 
– For special characters, please use Symbol and/or Arial Unicode. 
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3  Permissions 
• If excerpts from copyrighted works (including websites) such as illustrations, tables, animations, 
or text quotations are included in your manuscript, please obtain permission from the copyright 
holder (usually the original publisher) for both the print and online format. 
• Some publishers such as Springer have entrusted the Copyright Clearance Center in the US to 
manage the copyright permission procedure on their behalf. Please contact RightsLink for further 
information. Alternatively, Springer can provide you with a template to use when requesting 
permissions. 
►RightsLink 
• Please comply with the instructions stipulated in the permission(s) concerning acknowledgements 
or credit lines within your manuscript (e.g., reference to the copyright holder in captions) and 
keep the written confirmation of the permission in your possession with the copy of your manu-
script. 
• Please be aware that some publishers do not always grant right of reproduction for free due to 
different reasons. Springer will not be able to refund any costs that may have been incurred in re-
ceiving these permissions. As an alternative, material from other sources should be used. 
4  Manuscript Preparation 
To guarantee a smooth publication process and a seamless transformation of your manuscript into the 
final layout and various electronic formats (e.g., HTML for online publication, ePub for e-book readers), 
the manuscript needs to be structured as follows: 
• Front Matter: Title page, Dedication (optional), Foreword (optional), Preface (optional), Table of 
Contents, List of abbreviations (optional). 
• Text Body: It comprises the chapters containing the content of the book, i.e., text, figures, tables, 
and references. Chapters can be grouped together in parts. 
• Back Matter: After the last chapter, the back matter can contain an appendix, a glossary, and/or 
an index, all of which are optional.  
4.1  Front Matter 
The title page and the table of contents precede the actual content of a book.  
The preface (optional) should be about the book: why it was written, who it is for, its organization, or 
the selection of contributors. An introduction to the subject of the book, however, should appear as the 
first chapter of the book. 
Other optional items in the front matter at the beginning of a book are e.g., dedication, a foreword 
or a list of abbreviations. 
4.1.1  Title Page 
• Please include all author names (for contributed books, the editor names) and their affiliations, 
the book title and subtitle. Ensure that the sequence of the author names is correct and the title 
of your book is final when you submit your manuscript.  
• Please also supply all the email addresses and telephone numbers and in case of multiple authors 
or editors, clearly indicate the corresponding author or editor. 
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• Once the manuscript has been delivered to Springer Production, changes to title or authorship are 
no longer possible. 
4.1.2  Foreword (optional) 
•  If you intend to include a foreword, please submit it with the manuscript. 
Tip 
– A foreword is usually written by an authority on the subject, and serves as a recommendation of 
the book. 
– The name of the foreword’s contributor is always given at the end of the foreword; affiliations 
and titles are generally not included, but the date and place of writing may be. 
4.1.3  Preface (optional) 
• A preface should not contain a reference list. 
• An introduction to the subject of the book should not be confused with a preface. The introduc-
tion does not belong in the front matter, but should appear as the first chapter of the book.  
Tip 
– The preface should be about the book: why it was written, who it is for, its organization, or the 
selection of contributors. 
– Acknowledgments of support or assistance in preparing the book can be included as the last par-
agraph(s) of the preface. If the acknowledgment is more than one page long, it should start on a 
separate page under the heading Acknowledgments. 
4.1.4  Table of Contents 
• List all parts, chapters, and back matter material (e.g., an index) in the final sequence. 
• If your chapters are numbered, use Arabic numerals and number the chapters consecutively 
throughout the book (Chapter 1, Chapter 2, etc.), i.e., do not start anew with each part.  
• If there are parts, use Roman numerals for parts (Part I, Part II, etc.). 
1 
4.1.5  List of Abbreviations (optional) 
Key Style Points: Table of Contents 
Tip 
– A list of abbreviations and/or symbols is optional but it may be very helpful if numerous abbre-
viations and special symbols are scattered throughout the text. 
4.2  Chapters 
Chapters contain the actual content of the book, i.e., text, figures, tables, and references. Chapters can 
be grouped together in parts; subparts are not possible. Only one chapter (i.e., an introduction) may 
precede the first part and would be the first chapter. 
• Decide the numbering style for the chapters and apply this style consistently to all chapters: con-
secutively numbered (monographs or textbooks) or unnumbered (contributed volumes).  
• If an introduction to the subject of the book (historical background, definitions, or methodology) 
is included, it should appear as the first chapter and thus be included in the chapter numbering. It 
can contain references, figures, and tables, just as any other chapter.  
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4.2.1  Language  
• Either British or American English can be used, but be consistent within your chapter or book. In 
contributed books chapter-wise consistency is accepted. 
• Check for consistent spelling of names, terms, and abbreviations, including in tables and figure 
captions. 
Tip 
– For American spelling please consult Merriam–Webster's Collegiate Dictionary; for British 
spelling you should refer to Collins English Dictionary.  
– If English is not your native language, please ask a native speaker to help you or arrange for your 
text to be checked by a professional editing service. Please insert their final corrections into your 
data before submitting the manuscript.  
►More about language editing  
4.2.2  Chapter Title and Authors 
• For contributed volumes, please include each chapter’s authors’ names (spelled out as they would 
be cited), affiliations and e-mail addresses and telephone numbers after the chapter title.  
(The telephone number will not be published but may be needed as contact information during 
the publishing process.) 
1 
4.2.3  Abstract 
Key Style Points: Chapter Title Page 
• Begin each chapter with an abstract that summarizes the content of the chapter in 150 to 250 
words. The abstract will appear online at SpringerLink and be available with unrestricted access to 
facilitate online searching, using, e.g., Google, and allow unregistered users to read the abstract 
as a teaser for the complete chapter 
• If no abstract is submitted, we will use the first paragraph of the chapter instead. 
• Abstracts appear only in the printed edition of contributed volumes unless stipulated otherwise.  
Tip 
– Don’t include reference citations or undefined abbreviations in the abstract, since abstracts are 
often read independently of the actual chapter and without access to the reference list. 
– For further tips on writing an effective abstract, see the website on Search Engine Optimization. 
4.2.4  Keywords (if applicable) 
• Some books also publish keywords. Please check with the editor of your book or with the publish-
ing editor to see if keywords are required.  
Tip 
– Each keyword should not contain more than two compound words, and each keyword phrase 
should start with an uppercase letter. 
– When selecting the keywords, think of them as terms that will help someone locate your chapter 
at the top of the search engine list using, for example, Google. Very broad terms (e.g., ‘Case 
study’ by itself) should be avoided as these will result in thousands of search results but will not 
result in finding your chapter. 
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4.2.5  Headings and Heading Numbering 
• Heading levels should be clearly identified and each level should be uniquely and consistently 
formatted and/or numbered.  
• Use the decimal system of numbering if your headings are numbered.  
• Never skip a heading level. The only exceptions are run-in headings which can be used at any hi-
erarchical level.  
1 
Tip 
Key Style Points: Headings 
– In cross-references, for hyperlink purposes, refer to the chapter or section number (e.g., see 
Chap. 3 or see Sect. 3.5.1).   
– In addition to numbered headings, two more (lower) heading levels are possible. Their hierar-
chical level should be identified with the help of Springer’s templates or the standard Word or 
LaTeX heading styles. 
– Another option for lower level headings is a run-in heading, i.e., headings that are set immedi-
ately at the beginning of the paragraph. Such headings should be formatted in bold or italics. 
4.2.6  Terminology, Units and Abbreviations 
• Technical terms and abbreviations should be defined the first time they appear in the text.  
• Please always use internationally accepted signs and symbols for units, so-called SI units.  
• Numerals should follow the British/American method of decimal points to indicate decimals and 
commas to separate thousands. 
1 
Tip 
Key Style Points: Abbreviations, Numbers, Units and Equations 
– If the manuscript contains a large number of terms and abbreviations, a list of abbreviations or a 
glossary is advised. 
4.2.7  Formal Style and Text Formatting 
• Manuscripts will be checked by a copy editor for formal style. Springer follows certain standards 
with regard to the presentation of the content, and the copy editors make sure that the manu-
script conforms to these styles. 
1 
Tip 
Key Style Points: Formal Style, Text formatting 
– Remember not to make changes that involve only matters of style when you check your proofs. 
We have generally introduced forms that follow Springer’s house style. 
Emphasis and special type 
1 
Tip 
Key Style Points: Formal Style, Text formatting 
– Italics should be used for emphasized words or phrases in running text, but do not format entire 
paragraphs in italics.  
– In addition, use italics for species and genus names, mathematical/physical variables, and prefix-
es in chemical compounds. 
– Bold formatting should only be used for run-in headings and small capitals for indicating optical 
activity (D- and L-dopa). 
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– Sans serif (e.g., Arial) and nonproportional font (e.g., Courier) can be used to distinguish the lit-
eral text of computer programs from running text.  
Boxes  
• Do not set entire pages as boxes, because this affects online readability. 
Tip 
– Additional text elements for professional and text books such as examples, questions or exercis-
es, summaries or key messages can be highlighted with Springer’s manuscript preparation tool. If 
you do not use the tool, use a consistent style for each of these elements and submit a list of the 
styles used together with your manuscript.  
4.2.8  Footnotes 
• Always use footnotes instead of endnotes and never use footnotes instead of a reference list. 
• Footnotes should not consist of a reference citation. Footnotes should not contain figures, tables 
and/or the bibliographic details of a reference. 
1 
4.2.9  Equations and Program Code 
Key Style Points: Formal Style, Text formatting 
• In Word, use the Math function of Word 2007 or 2010, MathType, or Microsoft Equation Editor 
with Word 2003 to create your equations, and insert the graphic into your text file as an object.  
• In LaTeX, use the Math environment to create your equations. 
1 
Tip 
Key Style Points: Abbreviations, Numbers, Units and Equations 
– Prepare the whole equation in this way and not just part of it. 
4.3  Tables 
• Give each table a caption. Add a reference citation to the table source at the end of the caption, if 
necessary.  
• Number tables consecutively using the chapter number (e.g. Table 1.1 for the first table in 
Chap. 1) and ensure that all tables are cited in the text in sequential order. Do not write “the fol-
lowing table”. 
• Use the table function to create and format tables. Do not use the space bar or multiple tabs to 
separate columns and do not use Excel to create tables as this can cause problems when convert-
ing your tables into the typesetting program and other formats. 
1 
Tip 
Key Style Points: Tables and Lists 
– Simple, one-column lists should not be treated as tables. Use the displayed list function instead. 
– Save the tables in the same file as text, references, and figure captions. 
– Do not manually insert table rules in the manuscript, because they cannot be retained. 
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4.4  Figures and Illustrations 
4.4.1  Numbering 
• Number the figures chapter-wise using the chapter number (e.g., Fig. 1.1 for the first figure in 
Chap. 1) and ensure that all figures are cited in the text in sequential order. Do not write “the fol-
lowing figure”. 
4.4.2  Figure Captions 
• Give each figure a concise caption, describing accurately what the figure depicts. Include the cap-
tions at the end of the text file, not in the figure file.  
• Identify all elements found in the figure in the figure caption and use boxes, circles, etc. as coor-
dinate points in graphs instead of color lines. 
• If a figure is reproduced from a previous publication, include the source as the last item in the 
caption.  
1 
4.4.3  Figure and Illustration Files 
Key Style Points: Figures and Illustrations 
A figure is an object that is drawn or photographed. It does not consist solely of characters and thus 
cannot be keyed. 
• Do not submit tabular material as figures. 
• Graphics and diagrams should be saved as EPS files with the fonts embedded. Microsoft Office 
files (Excel or PowerPoint) can be submitted in the original format (xls, xlsx, ppt, pptx). Scanned 
graphics in TIFF format should have a minimum resolution of 1200 dpi.  
• Photos or drawings with fine shading should be saved as TIFF with a minimum resolution of 
300 dpi.  
• A combination of halftone and line art (e.g., photos containing line drawings or extensive letter-
ing, color diagrams, etc.) should be saved as TIFF with a minimum resolution of 600 dpi. 
Tip 
– Color figures will appear in color in the eBook but may be printed in black and white. In that 
case, do not refer to color in the captions and make sure that the main information will still be 
visible if converted to black and white. A simple way to check this is to make a black and white 
printout to see if the necessary distinctions between the different colors are still apparent. Color 
illustrations should be submitted as RGB (8 bits per channel).  
– Ensure consistency by using similar sizing and lettering for similar figures. Ideally, you should size 
figures to fit in the page or column width. For books in Springer’s standard format, the figures 
should be 78 mm or 117 mm (3 or 4 1/2 inches) wide and not higher than 198 mm (7 3/4 inches).  
– To add lettering, it is best to use Helvetica or Arial (sans serif fonts) and avoid effects such as 
shading, outline letters, etc. Keep lettering consistently sized throughout your final-sized art-
work, usually about 2–3 mm (8–12 pt). Variance of type size within an illustration should be min-
imal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label. 
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4.5  References  
4.5.1  Reference Citations 
• Cite references in the text with author name/s and year of publication in parentheses (“Harvard 
system”): 
– One author: (Miller 1991) or Miller (1991) 
– Two authors: (Miller and Smith 1994) or Miller and Smith (1994) 
– Three authors or more: (Miller et al. 1995) or Miller et al. (1995) 
• If it is customary in your field, you can also cite with reference numbers in square brackets either 
sequential by citation or according to the sequence in an alphabetized list: 
– [3, 7, 12].  
4.5.2  Reference List 
• Include a reference list at the end of each chapter so that readers of single chapters of the eBook 
can make full use of the citations. References at the end of the book cannot be linked to citations 
in the chapters. Please do not include reference lists at the end of a chapter section, at the end of 
a book part, in a preface or an appendix.  
• Include all works that are cited in the chapter and that have been published (including on the In-
ternet) or accepted for publication. Personal communications and unpublished works should only 
be mentioned in the text. Do not use footnotes as a substitute for a reference list.  
• Entries in the list must be listed alphabetically except in the numbered system of sequential cita-
tion. The rules for alphabetization are:  
– First, all works by the author alone, ordered chronologically by year of publication. 
– Next, all works by the author with a coauthor, ordered alphabetically by coauthor. 
– Finally, all works by the author with several coauthors, ordered chronologically by year of publi-
cation. 
Tip 
– For authors using EndNote software to create the reference list, Springer provides output styles 
that support the formatting of in-text citations and reference list.  
► EndNote software: Springer reference styles 
– For authors using BiBTeX, the style files are included in Springer’s LaTex package. 
4.5.3  Reference Styles 
Springer follows certain standards with regard to the presentation of the reference list. They are based 
on reference styles that were established for various disciplines in the past and have been adjusted to 
facilitate automated processing and citation linking. This allows us, for example, to easily cross link the 
cited references with the original publication. 
Tip 
– Always select one of the reference list styles that are supported by Springer and suits your publi-
cation best or follow the instructions received from your book editor. There are, however, rec-
ommended styles depending on the discipline.  
– The copy editor will check the references against the reference style applicable for the book and 
correct the format if necessary.  
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Springer Style Disciplines 
Key Style Points: 
Reference styles 
EndNote software: 
Springer reference 
styles 
Springer Basic Style  
Based on Harvard style and rec-
ommendations of the Council of 
Biology Editors (CBE) 
Medicine, Biomedicine, Life 
Sciences, Chemistry, Geosci-
ences, Computer Science, En-
gineering, Economics 
Springer Basic Style 
Springer Vancouver Style 
Springer Basic End-
Note Style 
Based on the NLM guidelines Cit-
ing Medicine 
Medicine, Biomedicine Springer Vancouver 
Style 
Springer MathPhys Style 
Springer Vancouver 
EndNote Style 
 
Mathematics, Physics, Statis-
tics 
Springer MathPhys 
Style 
Springer Physics Style 
Springer MathPhys 
EndNote Style 
Based on the reference list style 
of the American Physical Society 
(APS) 
Physics Springer Physics 
Style 
Springer SocPsych Style 
Springer Physics 
EndNote Style 
Based on the reference list style 
that was established by the 
American Psychological Associa-
tion (APA) 
Social Sciences, Psychology Springer SocPsych 
Style 
Springer Humanities Style 
Springer SocPsych 
EndNote Style 
Based on the reference list style 
as suggested by the Chicago 
Manual of Style (15th edn.) 
Humanities, Linguistics, Phi-
losophy 
Springer Humani-
ties Style 
4.6  Back Matter 
Springer Humani-
ties EndNote Style 
After the last chapter, the back matter of the book can contain an appendix, a glossary, and/or an in-
dex. 
• Do not include a reference list containing the cited literature in the back matter, as references are 
then not linked to citations in the chapters. Instead, include reference lists at the end of each 
chapter. A list of further reading may be included in the back matter.  
4.6.1  Appendix 
• An appendix cannot include a reference list. 
Tip 
– Include important original content within a chapter or a chapter appendix, not in the book ap-
pendix, as any appendix in the back matter of a book will appear with unrestricted access in the 
eBook on SpringerLink.  
4.6.2  Index (if applicable) 
• If an index is desired, please submit the index entries with the manuscript.  
Tip 
– Use the indexing function in Word or the index command in LaTeX to identify the index term as 
you write your text and indicate, on average, one or two index entry terms per manuscript page 
to be included in the index. 
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– Information should be listed under the term that most readers will probably look at first. Use 
cross-references to list variations or written-out versions and abbreviations/acronyms. 
– If you provide a list with index terms, the index, with page numbers, will be generated by our 
production partner. 
5  Final Check and Submission  
• Check the table of contents for the correct sequence of part, chapter and heading numbering and 
update the chapter titles and subheadings if necessary. 
• Save each chapter or contribution, including the accompanying references, figure legends, and 
tables, in a separate file in the original source file format and give each file your name and the 
chapter number (e.g., Myers-Chap1). Save the original figure files separately and name them with 
your name, the chapter, and figure number (e.g., Myers-Fig1.1).  
• Ensure the text and figures of your manuscript are complete and final and that you have kept to 
the agreed-upon length.  
• Submit your manuscript to your Springer Publishing Editor. Please include:  
– Original source files (Word, LaTeX) and figure files. 
– A PDF file of your manuscript and figure files, ideally with all fonts embedded, that can be used 
as a reference. This is especially important if text or figures contain special characters or unusual 
fonts. Please check the PDF to ensure that text appears as it should. 
• Ensure all third-party permissions have been obtained. 
• For contributed volumes, ensure that all signed Consent to Publish forms are enclosed in a sepa-
rate folder. 
• Submission is possible via FTP (please contact your Springer Publishing Editor for access details).  
• Before you submit your final manuscript, use the following Manuscript Submission Checklist to 
make sure you have covered everything.  
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Manuscript Submission Checklist 
Title page Title (and subtitle) final o  
Authors/Editors All author/editor names included o  
e-mail address of corresponding author included o  
Front matter Complete with the following elements: 
o  Dedication  o  Foreword  
o  Preface  o  Acknowledgments   
o  Table of contents (required)  o  List of contributors 
o  List of abbreviations 
o  
Table of contents Monographs: first 2 levels of headings appearing in chapters are included o  
Contributed books: chapter titles and author names included o  
Headings correspond to those in the text o  
Book structure Number of parts:             Number of chapters: o  
All chapters numbered sequentially throughout the book (or not numbered 
at all) 
o  
Chapter sequence and numbering final o  
Abstract Included for each chapter o  
Text Heading levels and special text elements consistently styled o  
No heading levels skipped o  
References Reference list included at the end of each chapter o  
Citations in text agree with reference list o  
Reference list style according to Springer’s guidelines  o  
Figures All figures mentioned in text enclosed, complete, and as separate files o  
Consecutively numbered within chapter o  
Consecutively cited in text o  
Figure captions included at the end of the text file o  
Tables Prepared with the table function o  
Consecutively numbered within chapter o  
Consecutively cited in text o  
Electronic manuscript File folder/zip archive labeled with book title and author/editor name  o  
Each chapter saved as a separate file in the original file format o  
Graphics saved as separate files in tif, eps, xls, xlsx, ppt, pptx format  o  
PDF file with all fonts embedded o  
Contributed books e-mail addresses and affiliation included for at least the corresponding au-
thor of each chapter 
o  
 Consent to publish for each chapter o  
Permissions Obtained for all material from other works o  
 
